

Approved



Zambia
Country Operational Plan
FY 2018



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		1,689,075		1,689,075	223,817	1,912,892
USAID		211,782,266	25,000,000	236,782,266	138,041	236,920,307
DOD		2,601,900		2,601,900	10,124,884	12,726,784
PC		5,070,621		5,070,621	0	5,070,621
HHS/CDC	2,412,531	122,211,606		124,624,137	0	124,624,137
HHS/HRSA		2,853,676		2,853,676	400,000	3,253,676
State/AF		491,583		491,583	0	491,583
Total	2,412,531	346,700,727	25,000,000	374,113,258	10,886,742	385,000,000

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency							Total
	State	DOD	HHS/CDC	HHS/HRSA	PC	State/AF	USAID	
CIRC		745,628	9,273,238		0	0	7,988,131	18,006,997
HBHC		0	6,068,302		18,805	0	15,787,457	21,874,564
HKID		528,071	254,510		0	251,500	22,393,888	23,427,969
HLAB		0	4,828,088	250,000	0	0	2,664,471	7,742,559
HMBL		0			0	0	0	0
HMIN		0			0	0	0	0
HTXD		0			0	0	58,620,663	58,620,663
HTXS		1,128,201	45,532,475	600,000	0	0	62,029,610	109,290,286
HVAB		0			179,045	0	5,080,700	5,259,745
HVCT		0	7,658,655		0	0	11,676,004	19,334,659
HVMS	1,561,616	0	6,807,464		4,693,725		7,208,470	20,271,275

Approved



HVOP		0	4,034,877		179,046	48,500	9,239,358	13,501,781
HVSI	127,459	200,000	12,708,944		0	0	3,813,660	16,850,063
HVTB		0	5,681,936		0	0	3,530,355	9,212,291
IDUP		0			0	0	0	0
MTCT		0	7,910,651	159,947	0	0	5,876,723	13,947,321
OHSS		0	2,529,148	1,343,729	0	191,583	4,839,593	8,904,053
PDCS		0	4,016,198		0	0	5,851,059	9,867,257
PDTX		0	7,319,651	500,000	0	0	10,182,124	18,001,775
	1,689,075	2,601,900	124,624,137	2,853,676	5,070,621	491,583	236,782,266	374,113,258



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount
HBHC	21,585,850
HKID	23,085,618
HVTB	9,037,809
PDCS	9,641,456
Total Technical Area Planned Funding:	63,350,733

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount
HLAB	6,842,269
HVSI	13,725,655
OHSS	7,718,694
Total Technical Area Planned Funding:	28,286,618

Technical Area: Prevention

Budget Code	Budget Code Planned Amount
CIRC	17,746,371
HMBL	0
HMIN	0
HVAB	5,152,950
HVCT	18,947,327
HVOP	13,171,457
IDUP	0
MTCT	13,508,774
Total Technical Area Planned Funding:	68,526,879

Approved



Technical Area: Treatment

Budget Code	Budget Code Planned Amount
HTXD	58,506,547
HTXS	108,437,106
PDTX	17,651,032
Total Technical Area Planned Funding:	184,594,685



Technical Area Summary Indicators and Targets

Indicator Number	Label	2019
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	95 %
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	437,266
	Number of new ANC and L&D clients	457,977
	By Age (Denominator): 10-14	754
	By Age (Denominator): <15-19	91,462
	By Age (Denominator): 20-24	131,532
	By Age (Denominator): 50+	606
	By Number of known positives: 15-19	114
	By Number of known positives: 20-24	5,579
	By Number of new positives: 15-19	629
	By Number of new positives: 20-24	6,482
	By Number of new positives: 50+	46
	By Number of new negative: 15-19	272
	By Number of new negative: 20-24	78,151
	By Number of new negative: 50+	74
	By Age (Numerator): 15-19	1,015
	By Age (Numerator): 20-24	90,216
	By Age (Numerator): 50+	230
PMTCT_STAT_D_DSD_Age_Sex		95,756



	25-29, Female	
	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	68,829
	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	68,808
	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	230
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Known at Entry Positive	7,695
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Newly Identified Negative	108,921
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Newly Identified Positive	6,322
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Known at Entry Positive	7,695
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Newly Identified Negative	83,365
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Newly Identified Positive	4,570
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female, Known at Entry Positive	6,175
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female, Newly Identified Negative	57,380
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female, Newly Identified Positive	4,717
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female, Newly Identified Positive	1,168



	KnownNewResult 40-49, Female, Known at Entry Positive	
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 40-49, Female, Newly Identified Negative	50,479
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 40-49, Female, Newly Identified Positive	7,430
	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	122,960
	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	95,514
	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	68,272
	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	59,055
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	13 %
	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	58,630
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	437,266
	New on ART	30,195
	Already on ART at beginning of current pregnancy	28,435
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male	338,874



	circumcision (VMMC) for HIV prevention program within the reporting period	
	By Age: 0-60 days	12
	By Age: 2 months - 9 years	70
	By Age: 10-14	16,982
	By Age: 15-19	134,300
	By Age: 20-24	80,939
	By Age: 25-29	54,711
	By Age: 50+	3,997
	By circumcision technique: Surgical VMMC	335,430
	By circumcision technique: Device-based VMMC	322
	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	17,039
	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	16,940
	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	13,884
PrEP_NEW_DSD	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	8,647
	Female 20-24	1,435
	FSW	4,751
	MSM	1,042
	PrEP_NEW_N_DSD_Age_Sex_v2	1,442



	25-29, Female	
	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	2,561
	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	2,157
	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	436
	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	431
	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	91
	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	94
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,247,058
	Age/sex: 10-14 Male	60,841
	Age/sex: 15-19 Male	62,872
	Age/sex: 20-24 Male	127,591
	Age/sex: 50+ Male	5,876
	Age/sex: 10-14 Female	62,134
	Age/sex: 15-19 Female	63,177
	Age/sex: 20-24 Female	297,681
	Age/sex: 50+ Female	6,186
	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	123,748



	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	62,608
	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	62,828
	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	62,818
	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	62,447
	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	62,765
	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	62,299
	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	61,187
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	48,153
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	9,397
	By key population type:	350



	Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	23,815
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	14,591
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	100 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	32,661
	Total number of registered new and relapsed TB cases, during the reporting period.	32,661
	Aggregated Age/Sex: Male <15	965



	(Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	19,752
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	870
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	11,074
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	965
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	19,752
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	870
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	11,074



HTS_SELF_DSD	HTS_SELF_N_DSD	320,767
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 10-14, Female, Directly-Assisted	3,166
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 10-14, Female, Unassisted	6,288
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 10-14, Male, Directly-Assisted	3,167
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 10-14, Male, Unassisted	6,288
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Female, Directly-Assisted	9,445
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Female, Unassisted	9,461
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Male, Directly-Assisted	6,324
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Male, Unassisted	6,306
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Female, Directly-Assisted	12,591
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Female, Unassisted	12,616
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Male, Directly-Assisted	12,628
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Male, Unassisted	12,624
	HTS_SELF_N_DSD_Age_Sex_HI	12,628



	VSelfTest 25-29, Female, Directly-Assisted	
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Female, Unassisted	12,629
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Male, Directly-Assisted	12,628
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Male, Unassisted	12,830
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Female, Directly-Assisted	12,628
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Female, Unassisted	12,830
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Male, Directly-Assisted	12,628
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Male, Unassisted	12,895
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Female, Directly-Assisted	12,628
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Female, Unassisted	13,131
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Male, Directly-Assisted	12,628
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Male, Unassisted	13,131
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Female, Directly-Assisted	12,628



HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Female, Unassisted	12,628
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Male, Directly-Assisted	12,628
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Male, Unassisted	12,608
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Female, Directly-Assisted	3,201
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Female, Unassisted	3,094
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Male, Directly-Assisted	3,146
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Male, Unassisted	3,364
HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	158,093
HTS_SELF_N_DSD_HIVSelfTest Unassisted	162,674
HTS_SELF_N_DSD_HIVSelfTestU ser Unassisted - Other	40,677
HTS_SELF_N_DSD_HIVSelfTestU ser Unassisted - Self	81,369
HTS_SELF_N_DSD_HIVSelfTestU ser Unassisted - Sex Partner	40,677
HTS_SELF_N_DSD_KeyPop_HIV SelfTest FSW, Directly-Assisted	94,203
HTS_SELF_N_DSD_KeyPop_HIV SelfTest FSW, Unassisted	106,416
HTS_SELF_N_DSD_KeyPop_HIV SelfTest MSM, Directly-Assisted	47,408



	HTS_SELF_N_DSD_KeyPop_HIV SelfTest MSM, Unassisted	59,328
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	3,050,817
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	5,366
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	122
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	2,934
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	35
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	5,866
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	321
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	1,519
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	138
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	5,160
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	333
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	3,155
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	108
	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	4,092
	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	226



	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	3,890
	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	463
	Service Delivery Point (Facility) Inpatient: 1-9, Negative	33,233
	Service Delivery Point (Facility) Inpatient: 1-9, Positive	608
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	4,347
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	103
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	971
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	22
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	3,596
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	102
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	894
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	92
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	15,031



	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	1,930
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	3,801
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	398
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	2,307
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	252
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	2,320
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	267
	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	8,590
	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	160
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	44,824
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	387
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	24,303
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	204
	Service Delivery Point (Facility)	72,390



	Other PITC: 15-19, Female, Negative	
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	1,209
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	18,314
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	697
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	68,101
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	2,876
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	46,266
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	3,919
	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	43,420
	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	3,584
	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	41,149
	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	6,097
	Service Delivery Point (Facility) Other PITC: 1-9, Negative	204,439
	Service Delivery Point (Facility) Other PITC: 1-9, Positive	4,959
	Service Delivery Point (Community) Other: 15-19, Female, Negative	2,445
	Service Delivery Point (Community)	176



	Other: 15-19, Female, Positive	
	Service Delivery Point (Community)	657
	Other: 15-19, Male, Negative	
	Service Delivery Point (Community)	44
	Other: 15-19, Male, Positive	
	Service Delivery Point (Community)	2,245
	Other: 20-24, Female, Negative	
	Service Delivery Point (Community)	80
	Other: 20-24, Female, Positive	
	Service Delivery Point (Community)	1,289
	Other: 20-24, Male, Negative	
	Service Delivery Point (Community)	91
	Other: 20-24, Male, Positive	
	Service Delivery Point (Community)	1,744
	Other: 50+, Female, Negative	
	Service Delivery Point (Community)	79
	Other: 50+, Female, Positive	
	Service Delivery Point (Community)	1,748
	Other: 50+, Male, Negative	
	Service Delivery Point (Community)	89
	Other: 50+, Male, Positive	
	Service Delivery Point (Facility)	69,294
	Pediatric : <5 Negative	
	Service Delivery Point (Facility)	1,406
	Pediatric : <5 Positive	
	Service Delivery Point (Facility) TB:	
	15-19, Female, Negative	931
	Service Delivery Point (Facility) TB:	
	15-19, Female, Positive	158
	Service Delivery Point (Facility) TB:	
	15-19, Male, Negative	452
	Service Delivery Point (Facility) TB:	
	15-19, Male, Positive	189
	Service Delivery Point (Facility) TB:	891



	20-24, Female, Negative	
	Service Delivery Point (Facility) TB: 20-24, Female, Positive	294
	Service Delivery Point (Facility) TB: 20-24, Male, Negative	941
	Service Delivery Point (Facility) TB: 20-24, Male, Positive	304
	Service Delivery Point (Facility) TB: 50+, Female, Negative	1,086
	Service Delivery Point (Facility) TB: 50+, Female, Positive	534
	Service Delivery Point (Facility) TB: 50+, Male, Negative	2,260
	Service Delivery Point (Facility) TB: 50+, Male, Positive	1,529
	Service Delivery Point (Facility) VMC: 10-14, Negative	18,028
	Service Delivery Point (Facility) VMC: 10-14, Positive	144
	Service Delivery Point (Facility) VMC: 15-19, Negative	99,376
	Service Delivery Point (Facility) VMC: 15-19, Positive	923
	Service Delivery Point (Facility) VMC: 20-24, Negative	99,175
	Service Delivery Point (Facility) VMC: 20-24, Positive	1,021
	Service Delivery Point (Facility) VMC: 50+, Negative	32,718
	Service Delivery Point (Facility) VMC: 50+, Positive	380
	Service Delivery Point (Facility) Index: 10-14, Female, Negative	2,869
	Service Delivery Point (Facility)	168



	Index: 10-14, Female, Positive	
	Service Delivery Point (Facility) Index: 10-14, Male, Negative	1,557
	Service Delivery Point (Facility) Index: 10-14, Male, Positive	83
	Service Delivery Point (Facility) Index: 15-19, Female, Negative	10,199
	Service Delivery Point (Facility) Index: 15-19, Female, Positive	914
	Service Delivery Point (Facility) Index: 15-19, Male, Negative	4,307
	Service Delivery Point (Facility) Index: 15-19, Male, Positive	777
	Service Delivery Point (Facility) Index: 20-24, Female, Negative	10,484
	Service Delivery Point (Facility) Index: 20-24, Female, Positive	1,180
	Service Delivery Point (Facility) Index: 20-24, Male, Negative	6,096
	Service Delivery Point (Facility) Index: 20-24, Male, Positive	1,753
	Service Delivery Point (Facility) Index: 50+, Female, Negative	8,613
	Service Delivery Point (Facility) Index: 50+, Female, Positive	2,578
	Service Delivery Point (Facility) Index: 50+, Male, Negative	5,752
	Service Delivery Point (Facility) Index: 50+, Male, Positive	4,073
	Service Delivery Point (Facility) Index: 1-9, Negative	17,782
	Service Delivery Point (Facility) Index: 1-9, Positive	1,131
	By Key Population: FSW, Negative	24,822



	By Key Population: FSW, Positive	3,688
	By Key Population: MSM, Negative	2,278
	By Key Population: MSM, Positive	161
	By Key Population: People in prisons and other enclosed settings, Negative	11,665
	By Key Population: People in prisons and other enclosed settings, Positive	1,671
	By Key Population: TG, Negative	463
	By Key Population: TG, Positive	54
	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	486
	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	87
	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	1,655
	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	132
	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	10,180
	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	1,681
	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	4,112
	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	1,179
	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	9,641
	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	2,159



	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	6,654
	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	1,853
	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	6,758
	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	2,935
	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	5,590
	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	4,253
	Service Delivery Point (Community) Index Mod: 1-9, Negative	20,495
	Service Delivery Point (Community) Index Mod: 1-9, Positive	1,387
	Service Delivery Point (Facility) ANC: 10-14, Negative	1,920
	Service Delivery Point (Facility) ANC: 10-14, Positive	91
	Service Delivery Point (Facility) ANC: 15-19, Negative	78,396
	Service Delivery Point (Facility) ANC: 15-19, Positive	4,458
	Service Delivery Point (Facility) ANC: 20-24, Negative	108,332
	Service Delivery Point (Facility) ANC: 20-24, Positive	6,231
	Service Delivery Point (Facility) ANC: 50+, Negative	6,393
	Service Delivery Point (Facility) ANC: 50+, Positive	371
	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	13,383



	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	315
	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	7,397
	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	49
	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	67,618
	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	1,754
	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	18,146
	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	575
	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	58,271
	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	3,413
	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	34,877
	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	1,660
	Service Delivery Point (Facility) VCT: 50+, Female, Negative	44,860
	Service Delivery Point (Facility) VCT: 50+, Female, Positive	3,350
	Service Delivery Point (Facility) VCT: 50+, Male, Negative	43,220
	Service Delivery Point (Facility) VCT: 50+, Male, Positive	5,220
	Service Delivery Point (Facility) VCT: 1-9, Negative	82,509
	Service Delivery Point (Facility) VCT: 1-9, Positive	1,683



	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	949
	Service Delivery Point (Community) VCT Mod: 10-14, Female, Positive	25
	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	470
	Service Delivery Point (Community) VCT Mod: 10-14, Male, Positive	5
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	10,617
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	370
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	3,261
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	177
	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	9,795
	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	758
	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	4,902
	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	362
	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	7,342
	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	483
	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	6,528
	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	483
	Service Delivery Point (Community) VCT Mod: 1-9, Negative	5,524



	Service Delivery Point (Community) VCT Mod: 1-9, Positive	112
	HTS_TST_N_DSD_EW_Age_Sex_ Result 10-14, Female, Negative	420
	HTS_TST_N_DSD_EW_Age_Sex_ Result 10-14, Female, Positive	1
	HTS_TST_N_DSD_EW_Age_Sex_ Result 10-14, Male, Negative	213
	HTS_TST_N_DSD_EW_Age_Sex_ Result 10-14, Male, Positive	1
	HTS_TST_N_DSD_EW_Age_Sex_ Result 15-19, Female, Negative	4,567
	HTS_TST_N_DSD_EW_Age_Sex_ Result 15-19, Female, Positive	105
	HTS_TST_N_DSD_EW_Age_Sex_ Result 15-19, Male, Negative	1,220
	HTS_TST_N_DSD_EW_Age_Sex_ Result 15-19, Male, Positive	10
	HTS_TST_N_DSD_EW_Age_Sex_ Result 1-9, Unknown Sex, Negative	2,748
	HTS_TST_N_DSD_EW_Age_Sex_ Result 1-9, Unknown Sex, Positive	37
	HTS_TST_N_DSD_EW_Age_Sex_ Result 20-24, Female, Negative	4,068
	HTS_TST_N_DSD_EW_Age_Sex_ Result 20-24, Female, Positive	79
	HTS_TST_N_DSD_EW_Age_Sex_ Result 20-24, Male, Negative	2,432
	HTS_TST_N_DSD_EW_Age_Sex_ Result 20-24, Male, Positive	4
	HTS_TST_N_DSD_EW_Age_Sex_ Result 25-29, Female, Negative	2,327
	HTS_TST_N_DSD_EW_Age_Sex_ Result 25-29, Female, Positive	39



HTS_TST_N_DSD_EW_Age_Sex_ Result 25-29, Male, Negative	2,505
HTS_TST_N_DSD_EW_Age_Sex_ Result 25-29, Male, Positive	27
HTS_TST_N_DSD_EW_Age_Sex_ Result 30-34, Female, Negative	2,327
HTS_TST_N_DSD_EW_Age_Sex_ Result 30-34, Female, Positive	39
HTS_TST_N_DSD_EW_Age_Sex_ Result 30-34, Male, Negative	2,506
HTS_TST_N_DSD_EW_Age_Sex_ Result 30-34, Male, Positive	27
HTS_TST_N_DSD_EW_Age_Sex_ Result 35-39, Female, Negative	2,327
HTS_TST_N_DSD_EW_Age_Sex_ Result 35-39, Female, Positive	39
HTS_TST_N_DSD_EW_Age_Sex_ Result 35-39, Male, Negative	2,506
HTS_TST_N_DSD_EW_Age_Sex_ Result 35-39, Male, Positive	27
HTS_TST_N_DSD_EW_Age_Sex_ Result 40-49, Female, Negative	2,327
HTS_TST_N_DSD_EW_Age_Sex_ Result 40-49, Female, Positive	39
HTS_TST_N_DSD_EW_Age_Sex_ Result 40-49, Male, Negative	2,506
HTS_TST_N_DSD_EW_Age_Sex_ Result 40-49, Male, Positive	27
HTS_TST_N_DSD_EW_Age_Sex_ Result 50+, Female, Negative	3,251
HTS_TST_N_DSD_EW_Age_Sex_ Result 50+, Female, Positive	4
HTS_TST_N_DSD_EW_Age_Sex_ Result 50+, Male, Negative	3,228



	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Positive	57
	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	5,790
	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	1,976
	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	5,406
	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	2,784
	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	5,751
	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	1,976
	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	5,381
	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	2,794
	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	5,723
	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	1,964
	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	5,334
	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	2,804
	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	5,755
	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	1,986
	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	5,394
	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	2,816



	HTS_TST_N_DSD_Inpat_Age_Sex _Result 25-29, Female, Negative	2,862
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 25-29, Female, Positive	316
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 25-29, Male, Negative	3,002
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 25-29, Male, Positive	385
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 30-34, Female, Negative	2,862
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 30-34, Female, Positive	316
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 30-34, Male, Negative	3,002
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 30-34, Male, Positive	385
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Female, Negative	2,862
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Female, Positive	316
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Male, Negative	3,002
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Male, Positive	385
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Female, Negative	2,862
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Female, Positive	316
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Negative	3,002
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Positive	385
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Female,	1,702



	Negative	
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	192
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	1,803
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	288
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	1,742
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	186
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	1,814
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	274
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	1,702
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	202
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	1,793
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	262
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	1,722
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	202



HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	1,756
HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	262
HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	3,255
HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	709
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	5,809
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	2,095
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	5,679
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	2,493
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	5,707
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	2,126
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	5,699
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	2,472
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	5,730
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	2,100



HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	5,822
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	2,496
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	5,711
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	2,099
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	5,645
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	2,442
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	33,863
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	2,740
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	33,626
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	5,085
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	33,693
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	2,646
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	33,376
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	5,085



HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	33,313
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	2,646
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	33,376
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	5,085
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	33,313
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	2,646
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	33,376
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	5,085
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	1,214
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Positive	124
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	1,343
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	95
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	1,214
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Positive	124



	Positive	
	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	1,343
	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	95
	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	1,214
	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	124
	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	1,343
	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	95
	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	1,214
	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	124
	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	1,343
	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	95
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	75,041
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	4,360
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	56,274



HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	3,273
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	37,502
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	2,163
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	18,769
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	1,077
HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Female, Negative	512
HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Female, Positive	118
HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Male, Negative	367
HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Male, Positive	29
HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	4,876
HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	282
HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	1,160
HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	56
HTS_TST_N_DSD_STI_Age_Sex_Result 1-9, Unknown Sex, Negative	1
HTS_TST_N_DSD_STI_Age_Sex_	4,045



	Result 20-24, Female, Negative	
	HTS_TST_N_DSD_STI_Age_Sex_ Result 20-24, Female, Positive	299
	HTS_TST_N_DSD_STI_Age_Sex_ Result 20-24, Male, Negative	2,026
	HTS_TST_N_DSD_STI_Age_Sex_ Result 20-24, Male, Positive	383
	HTS_TST_N_DSD_STI_Age_Sex_ Result 25-29, Female, Negative	2,113
	HTS_TST_N_DSD_STI_Age_Sex_ Result 25-29, Female, Positive	262
	HTS_TST_N_DSD_STI_Age_Sex_ Result 25-29, Male, Negative	2,177
	HTS_TST_N_DSD_STI_Age_Sex_ Result 25-29, Male, Positive	358
	HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Female, Negative	2,103
	HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Female, Positive	262
	HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Male, Negative	2,184
	HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Male, Positive	348
	HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Female, Negative	2,083
	HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Female, Positive	262
	HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Male, Negative	2,164
	HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Male, Positive	348
	HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Female, Negative	2,073
	HTS_TST_N_DSD_STI_Age_Sex_	262



	Result 40-49, Female, Positive	
	HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Male, Negative	2,164
	HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Male, Positive	348
	HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Female, Negative	2,855
	HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Female, Positive	379
	HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Male, Negative	2,719
	HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Male, Positive	555
	HTS_TST_N_DSD_TBC_Age_Sex_ _Result 25-29, Female, Negative	837
	HTS_TST_N_DSD_TBC_Age_Sex_ _Result 25-29, Female, Positive	392
	HTS_TST_N_DSD_TBC_Age_Sex_ _Result 25-29, Male, Negative	870
	HTS_TST_N_DSD_TBC_Age_Sex_ _Result 25-29, Male, Positive	449
	HTS_TST_N_DSD_TBC_Age_Sex_ _Result 30-34, Female, Negative	837
	HTS_TST_N_DSD_TBC_Age_Sex_ _Result 30-34, Female, Positive	392
	HTS_TST_N_DSD_TBC_Age_Sex_ _Result 30-34, Male, Negative	870
	HTS_TST_N_DSD_TBC_Age_Sex_ _Result 30-34, Male, Positive	449
	HTS_TST_N_DSD_TBC_Age_Sex_ _Result 35-39, Female, Negative	837
	HTS_TST_N_DSD_TBC_Age_Sex_ _Result 35-39, Female, Positive	392
	HTS_TST_N_DSD_TBC_Age_Sex	870



	_Result 35-39, Male, Negative	
	HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Male, Positive	449
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Female, Negative	837
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Female, Positive	392
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Negative	865
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Positive	449
	HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Negative	33,058
	HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Positive	2,457
	HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Negative	34,747
	HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Positive	3,564
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Negative	33,300
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Positive	2,457
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Negative	34,399
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Positive	3,564
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Female, Negative	33,332
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Female, Positive	2,457
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Male, Negative	34,771
	HTS_TST_N_DSD_VCT_Age_Sex	3,564



	_Result 35-39, Male, Positive	
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Negative	33,032
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Positive	2,457
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Negative	34,520
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Positive	3,564
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Female, Negative	4,902
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Female, Positive	362
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Male, Negative	4,902
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Male, Positive	509
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 30-34, Female, Negative	4,902
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 30-34, Female, Positive	379
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 30-34, Male, Negative	4,902
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 30-34, Male, Positive	542
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 35-39, Female, Negative	4,902
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 35-39, Female,	362



	Positive	
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	4,902
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	566
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	4,902
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Positive	362
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	4,902
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	483
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	21,612
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	181
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	21,612
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	181
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	21,612
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	181
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	21,612
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	181
GEND_GBV_DSD	Number of people receiving post-GBV care	7,916
	By type of service: Physical and/or	2,519



	Emotional Violence (Other Post-GBV Care)	
	By type of service: Sexual Violence (Post-Rape Care)	5,397
	By PEP service provision (related to sexual violence services provided)	2,516
	<10, Female, Physical and/or Emotional Violence	237
	<10, Female, Sexual Violence (Post-Rape Care)	805
	<10, Male, Physical and/or Emotional Violence	214
	<10, Male, Sexual Violence (Post-Rape Care)	30
	10-14, Female, Physical and/or Emotional Violence	241
	10-14, Female, Sexual Violence (Post-Rape Care)	985
	10-14, Male, Physical and/or Emotional Violence	71
	10-14, Male, Sexual Violence (Post-Rape Care)	13
	15-19, Female, Physical and/or Emotional Violence	492
	15-19, Female, Sexual Violence (Post-Rape Care)	801
	15-19, Male, Physical and/or Emotional Violence	60
	15-19, Male, Sexual Violence (Post-Rape Care)	14
	20-24, Female, Physical and/or Emotional Violence	1,021
	20-24, Female, Sexual Violence	2,622



	(Post-Rape Care)	
	20-24, Male, Physical and/or Emotional Violence	83
	20-24, Male, Sexual Violence (Post-Rape Care)	1
	50+, Female, Physical and/or Emotional Violence	132
	50+, Female, Sexual Violence (Post-Rape Care)	60
	50+, Male, Physical and/or Emotional Violence	26
	50+, Male, Sexual Violence (Post-Rape Care)	5
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	373,842
	Age/Sex: 10-14 Male	73,415
	Age/Sex: 15-17 Male	64,752
	By: Age/sex: Male 18-24	7,785
	Age/Sex: 10-14 Female	73,524
	Age/Sex: 15-17 Female	73,327
	By: Age/sex: 18-24 Female	12,511
	Sum of Age/Sex disaggregates	285,018
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	2,335
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	1,147
Required only for DREAMS countries - By service, age and	292	



	sex: Education Support Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	2,272
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	1,229
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	254
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	6,262
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	5,285
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	2,133
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	2,588
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	6,135
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	5,390



	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	1,880
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	1,472
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	7,269
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	4,950
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	3,395
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	6,708
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	4,807
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	3,115
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	7,639
	Required only for DREAMS countries - By service, age and	6,207



	sex: Economic Strengthening Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	5,167
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	6,911
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	6,019
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	3,780
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	2,113
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	1,966
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	1,610
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	1,719
	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	1,684
	Required only for DREAMS countries - By service, age and	1,612



	sex: Other Services Male 18-24	
	Age/Sex: <1	7,310
	Age/Sex: 1-9	61,218
	Program Completion: Active	157,784
	Program Completion: Graduation	216,058
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	9,715
	Age/Sex: 10-14 Male	1,400
	Age/Sex: 15-17 Male	400
	By age/sex: 18-24 Male	0
	By age/sex: 25+ Male	410
	Age/Sex: 10-14 Female	1,400
	Age/Sex: 15-17 Female	1,400
	By age/sex: 18-24 Female	200
	By age/sex: 25+ Female	1,297
	Sum of Age/Sex disaggregates	4,600
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 10-14	1,100
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 15-17	30
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 18-24	1,007
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 25+	800



	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 10-14	1,100
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 15-17	242
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 18-24	535
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 25+	610
	Program Completion: Graduated	9,715
OVC_HIVSTAT_DSD	OVC_HIVSTAT_DSD Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	88 %
	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	328,214
	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	373,842
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and	17,864



	relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	611
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6,645
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	798
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	9,687
TB_PREV_DSD	TB_PREV_DSD TB_PREV_DSD	58 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6	123,539



	months of Isoniazid Preventive Therapy (IPT) during the reporting period	
	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	211,279
	By Age/Sex (Denominator): <15, Female	5,956
	By Age/Sex (Denominator): <15, Male	4,906
	By Age/Sex (Denominator): 15+, Female	120,922
	By Age/Sex (Denominator): 15+, Male	79,432
	By Age/Sex (Numerator): <15, Female	4,288
	By Age/Sex (Numerator): <15, Male	1,613
	By Age/Sex (Numerator): 15+, Female	58,542
	By Age/Sex (Numerator): 15+, Male	59,096
	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	211,216
	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	123,539



TX_TB_DSD	TX_TB_DSD The proportion of ART patients who were screened who are receiving TB treatment	0 %
	Number of ART patients who were screened for TB at least once during the reporting period	1,086,616
	Denominator: By Aggregated Age/Sex: <15, Female	43,569
	Denominator: By Aggregated Age/Sex: <15, Male	32,703
	Denominator: By Aggregated Age/Sex:15+, Female	587,124
	Denominator: By Aggregated Age/Sex:15+, Male	424,311
	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,086,616
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	1,086,616
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	1,086,616
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	58,630
	By infants who received a virologic test within 2 months of birth	46,883
	By infants who received their first virologic HIV test between 2 and 12	11,747



	months of age	
	Sum of Infant Age disaggregates	58,630
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,103,870
	Age/Sex: 15-19 Male	17,956
	Age/Sex: 15-19 Female	28,666
	Age/Sex: <1	14,802
	Age/Sex: <1-9	31,521
	Age/Sex: 10-14 Male	7,423
	Age/Sex: 10-14 Female	14,709
	Age/Sex: 20-24 Male	21,303
	Age/Sex: 50+ Male	63,756
	Age/Sex: 20-24 Female	61,070
	Age/Sex: 50+ Female	76,901
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Female, Positive	82,583
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Male, Positive	40,801
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Female, Positive	103,566
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Male, Positive	61,803
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Female, Positive	98,247
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Male, Positive	73,080
TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Female, Positive	146,375	
TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Male, Positive	159,343	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral	192,934



	therapy (ART)	
	By Age/Sex: <1	164
	By Age/Sex: 1-9	10,803
	By Age/Sex: 10-14 Male	1,784
	By Age/Sex: 15-19 Male	4,676
	By Age/Sex: 20-24 Male	4,763
	By Age/Sex: 50+ Male	27,076
	By Age/Sex: 10-14 Female	1,700
	By Age/Sex: 15-19 Female	4,271
	By Age/Sex: 20-24 Female	6,915
	By Age/Sex: 50+ Female	16,105
	Pregnancy status	19,318
	Breastfeeding status	34,685
	FSW	4,044
	MSM	4,340
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Female, Positive	11,056
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Male, Positive	7,258
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Female, Positive	14,356
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Male, Positive	10,139
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Female, Positive	13,342
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Male, Positive	11,602
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Female, Positive	21,563
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Male, Positive	25,316
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result	0 %



	documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,102,206
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	31,885
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	438,008
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	38,675
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	591,721
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	90 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	241,059
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	267,837
	Numerator by Status: Pregnant	49,556
	Numerator by Status: Breastfeeding	13,075



	Denominator by Status: Pregnant	54,190
	Denominator by Status: Breastfeeding	14,274
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,722
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	92,807
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10,182
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	130,348
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,449
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	105,707



	including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11,164
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	142,517



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
10207	American International Health Alliance Twinning Center	NGO	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	1,293,729
10225	Eastern Province Health Office	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,006,326
10227	Western Province Health Office	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,682,971
10236	University Teaching Hospital	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	12,549,495



10274	New Partner	TBD	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	733,451
10984	Project Concern International	NGO	U.S. Department of Defense		
11027	National HIV/AIDS/STI/TB Council - Zambia	Parastatal	U.S. Department of State/Bureau of African Affairs	GHP-State	191,583
11626	JHPIEGO	University	U.S. Department of Defense		
11627	U.S. Department of Defense (Defense)	Other USG Agency	U.S. Department of Defense	GHP-State	1,328,201
12272	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	251,500
13076	John Snow, Inc.	Private Contractor	U.S. Department of Defense		
13580	CENTER FOR INFECTIOUS DISEASE AND RESEARCH IN ZAMBIA	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	29,783,051
14339	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	48,500
14420	Lusaka Provincial Health Office	Host Country Government Agency	U.S. Department of Health and Human	GHP-State	4,031,175



			Services/Centers for Disease Control and Prevention		
14421	Southern Provincial Health Office	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,583,161
14452	Population Services International	NGO	U.S. Department of Defense	GHP-State	745,628
14507	FHI 360	NGO	U.S. Department of Defense		
16634	Expanded Church Response Trust	NGO	U.S. Agency for International Development	GHP-State	7,893,213
17396	Society for Family Health	NGO	U.S. Agency for International Development	GHP-State	400,000
17399	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State	19,903,870
17400	Program for Appropriate Technology in Health	NGO	U.S. Agency for International Development	GHP-State	1,860,000
17403	World Vision International	FBO	U.S. Agency for International Development		
17410	Pact	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	15,066,954



17413	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State	24,553,204
17422	FHI 360	NGO	U.S. Agency for International Development	GHP-State	3,516,060
17425	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	2,771,091
17478	Clinical and Laboratory Standards Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,236,046
17479	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	750,000
17497	University of Maryland	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	14,984,205
17499	Tropical Diseases Research Centre	Parastatal	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	1,274,868



			Prevention		
17513	Ministry of Health, Zambia	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,955,000
17514	Johns Hopkins University Bloomberg School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,950,000
17788	Development Aid from People to People Humana Zambia	NGO	U.S. Agency for International Development	GHP-State	7,172,253
17873	Ministry of Health, Zambia	Host Country Government Agency	U.S. Agency for International Development	GHP-State	3,000,000
18159	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State, GHP-USAID	99,482,465
18160	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State	5,261,316
18161	Remote Medical International	Private Contractor	U.S. Agency for International Development	GHP-State	4,615,500
18263	UNICEF	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	2,200,000
18278	TBD	TBD	Redacted	Redacted	Redacted



18297	World Health Organization	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	200,000
18304	Right To Care, South Africa	NGO	U.S. Agency for International Development	GHP-State	18,905,802
18322	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	559,947
18323	Broadreach	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	9,727,234
18324	University of Maryland Baltimore	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,171,034
18325	University of Zambia	University	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	250,000



			Control and Prevention		
18327	Catholic Relief Services	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	11,897,776
18332	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	200,000
18346	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	376,896
18487	TBD	TBD	Redacted	Redacted	Redacted
18527	TBD	TBD	Redacted	Redacted	Redacted
18528	TBD	TBD	Redacted	Redacted	Redacted
18530	JHPIEGO	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	1,000,000
18532	TBD	TBD	Redacted	Redacted	Redacted
18652	Johns Hopkins University Center for Communication Programs	University	U.S. Agency for International Development	GHP-State	656,517
18669	TBD	TBD	Redacted	Redacted	Redacted

Approved



70432	TBD	TBD	Redacted	Redacted	Redacted
70453	TBD	TBD	Redacted	Redacted	Redacted
70455	Chemonics International	Private Contractor	U.S. Agency for International Development	GHP-State	3,090,530



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 10207	Mechanism Name: Twinning Centre
Funding Agency: HHS/HRSA	Procurement Type: Grant
Prime Partner Name: American International Health Alliance Twinning Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,293,729	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 100,000	
Total All Funding Sources and Applied Pipeline Amount: 1,393,729	
Funding Source	Funding Amount
GHP-State	1,293,729

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 10207		
Mechanism Name: Twinning Centre		
Prime Partner Name: American International Health Alliance Twinning Center		
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	250,000
Strategic Area	Budget Code	Planned Amount



Governance and Systems	OHSS	543,729
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	500,000

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10225	Mechanism Name: EPHO Follow On
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Eastern Province Health Office	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 2,006,326	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,006,326	
Funding Source	Funding Amount
GHP-State	2,006,326

Cross-Cutting Budget Attribution(s)

Human Resources for Health	850,000
----------------------------	---------

Budget Code Information

Mechanism ID:	10225
----------------------	--------------



Mechanism Name: EPHO Follow On		
Prime Partner Name: Eastern Province Health Office		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	461,425
Strategic Area	Budget Code	Planned Amount
Care	HVTB	131,835
Strategic Area	Budget Code	Planned Amount
Care	PDCS	54,931
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	40,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	113,697
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	565,300
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	143,222
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	436,437
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	59,479

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
-------------------------	--------------	-------------

VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	9,310
VMMC_CIRC_DSD	By Age: 10-14	466
VMMC_CIRC_DSD	By Age: 15-19	3,725
VMMC_CIRC_DSD	By Age: 20-24	2,235
VMMC_CIRC_DSD	By Age: 25-29	1,489
VMMC_CIRC_DSD	By Age: 50+	94
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	6,520
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	8,009
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	9,310
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	466
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	465
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	370
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	150
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	50
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	100
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	9,590
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	545
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	4



HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	2,848
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	2,766
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	922
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	603
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	603
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	603
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	603
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	6

Implementing Mechanism Details

Mechanism ID: 10227	Mechanism Name: WPHO Follow on
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Western Province Health Office	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC



Total All Funding Sources: 2,682,971	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,682,971	
Funding Source	Funding Amount
GHP-State	2,682,971

Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,100,000
----------------------------	-----------

Budget Code Information

Mechanism ID: 10227		
Mechanism Name: WPHO Follow on		
Prime Partner Name: Western Province Health Office		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	563,456
Strategic Area	Budget Code	Planned Amount
Care	HVTB	136,595
Strategic Area	Budget Code	Planned Amount
Care	PDCS	51,223
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	40,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	139,952
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	500,000
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	239,591
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	955,332
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	56,822

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	9,994
VMMC_CIRC_DSD	By Age: 0-60 days	1
VMMC_CIRC_DSD	By Age: 2 months - 9 years	3
VMMC_CIRC_DSD	By Age: 10-14	481
VMMC_CIRC_DSD	By Age: 15-19	4,000
VMMC_CIRC_DSD	By Age: 20-24	2,418
VMMC_CIRC_DSD	By Age: 25-29	1,607
VMMC_CIRC_DSD	By Age: 50+	120
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	7,019
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	8,626
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	9,994
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	483
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	482
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	399
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12	10,004



	months	
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	524
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	2,967
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	2,967
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	988
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	617
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	617
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	617
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	617
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	5

Implementing Mechanism Details

Mechanism ID: 10236	Mechanism Name: University Teaching Hospital
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University Teaching Hospital	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC
Total All Funding Sources: 12,549,495	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 12,549,495	
Funding Source	Funding Amount
GHP-State	12,549,495

Cross-Cutting Budget Attribution(s)

Gender: GBV	300,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Key Populations: FSW	120,000
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Collection and use of strategic information on SWs and clients
Key Populations: MSM and TG	30,000
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Collection and use of strategic information
Human Resources for Health	500,000
Education	80,000
Food and Nutrition: Policy, Tools, and Service Delivery	110,000



Budget Code Information

Mechanism ID: 10236		
Mechanism Name: University Teaching Hospital		
Prime Partner Name: University Teaching Hospital		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	500,000
Strategic Area	Budget Code	Planned Amount
Care	HKID	251,323
Strategic Area	Budget Code	Planned Amount
Care	HVTB	500,000
Strategic Area	Budget Code	Planned Amount
Care	PDCS	636,847
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	307,010
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	100,000
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,043,384
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	95,168
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	515,763
Strategic Area	Budget Code	Planned Amount



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	7,600,000
Treatment	PDTX	1,000,000

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,856
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	18,043
PMTCT_ART_DSD	New on ART	1,387
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,469
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	18,043
PMTCT_STAT_DSD	Number of new ANC and L&D clients	19,208
PMTCT_STAT_DSD	By Age (Denominator): 10-14	22
PMTCT_STAT_DSD	By Age (Denominator): <15-19	3,830
PMTCT_STAT_DSD	By Age (Denominator): 20-24	6,072
PMTCT_STAT_DSD	By Age (Denominator): 50+	3
PMTCT_STAT_DSD	By Number of known positives: 20-24	282
PMTCT_STAT_DSD	By Number of new positives: 15-19	22
PMTCT_STAT_DSD	By Number of new positives: 20-24	338
PMTCT_STAT_DSD	By Number of new negative: 20-24	3,210
PMTCT_STAT_DSD	By Age (Numerator): 15-19	22
PMTCT_STAT_DSD	By Age (Numerator): 20-24	3,830
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	3,533



PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	2,874
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	2,874
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	401
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	5,087
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	336
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	401
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	2,892
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	240
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	322
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	2,348
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	204
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	63
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	1,650
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	247
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	5,824
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	3,533
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	2,874
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	1,960
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	588
PrEP_NEW_DSD	Female 20-24	97



PrEP_NEW_DSD	FSW	112
PrEP_NEW_DSD	MSM	73
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	97
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	176
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	146
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	30
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	30
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	6
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	6
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	5,500
PP_PREV_DSD	Age/sex: 10-14 Male	311
PP_PREV_DSD	Age/sex: 15-19 Male	311
PP_PREV_DSD	Age/sex: 20-24 Male	607
PP_PREV_DSD	Age/sex: 50+ Male	30
PP_PREV_DSD	Age/sex: 10-14 Female	318
PP_PREV_DSD	Age/sex: 15-19 Female	324
PP_PREV_DSD	Age/sex: 20-24 Female	1,251
PP_PREV_DSD	Age/sex: 50+ Female	38
PP_PREV_DSD	Sum of Age/Sex disaggregates	3,190
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	590
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	246
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	246
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	246
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	246
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	246
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	246
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	244
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum	3,066

	standards required	
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	200
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	260
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,606
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	79,821
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	199
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	107
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	162
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	42
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	142



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	87
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	112
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	107
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	1,222
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	22
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	39
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	8
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	22
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	18
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	11
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	14



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	14
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	80
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1,649
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	896
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,992
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	506
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	1,689
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	44
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	930
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	68



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	1,198
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	98
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,137
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	169
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	7,524
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	184
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	13
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	13
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	6
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	10
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	2,548
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	51
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	40
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	18



HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	37
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	40
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	46
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	96
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	65
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	108
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	59
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	306
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	143
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	36
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female,	311



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	50
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	191
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	66
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	266
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	90
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	184
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	131
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	652
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	43
HTC_TST_DSD	By Key Population: FSW, Negative	567
HTC_TST_DSD	By Key Population: FSW, Positive	85
HTC_TST_DSD	By Key Population: MSM, Negative	5
HTC_TST_DSD	By Key Population: MSM, Positive	1
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	22
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	4
HTC_TST_DSD	By Key Population: TG, Negative	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	11
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	110
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	46



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	110
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	43
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	110
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	60
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	110
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	60
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	110
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	60
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	110
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	66
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	142
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	77
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	3,148
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	246
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	4,352
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	341
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	262
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	499



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	275
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	1,910
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	52
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	502
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	1,602
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	94
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	977
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	46
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	1,238
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	91
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	1,195
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	148
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	3,052
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	61
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	6



HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	59
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	17
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	55
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	27
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	41
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	36
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 1-9, Negative	39
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Negative	8
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Negative	125

HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Negative	36
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	101
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative	111
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	66
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	64
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Negative	64
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Negative	64
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative	64
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Negative	86
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Negative	89
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	186



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	70
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	173
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	93
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	194
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	70
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	173
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	93
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	186
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	70
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	173
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	93
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	191
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	70
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	173
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	95
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	78
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	9



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	83
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	78
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	83
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	78
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	83
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	78
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	83
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	11
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	11

HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	11
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	11
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	11
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	11
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	11
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	11
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	60

HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	60
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	60
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	60
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	60
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	60
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	60
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	60
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	917
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	922



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	142
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	917
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	922
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	142
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	917
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	922
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	142
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	917
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	922
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	142
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	7
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	7



HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	7
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	7
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	3,014
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	240
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	2,260
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	176
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	1,507
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	119
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	754
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	60
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Female, Negative	15
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Male, Negative	12
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	103



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	28
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	90
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	47
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	49
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	52
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	49
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	52
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	49
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	52



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	49
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	52
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	68
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	63
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	34
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	35
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	34
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	35
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	19



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	34
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	35
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	34
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	35
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	911
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	67
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	999
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	100
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	911
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	67
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	951
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	100
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	911



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	67
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	992
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	100
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	911
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	67
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	951
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	100
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Negative	27
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Negative	27
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Negative	27
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	27
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	27
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Positive	2

HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	27
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	27
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	27
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	3
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,837
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,837
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	22
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,111
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	27
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	677
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	22
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,111



TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	27
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	677
GEND_GBV_DSD	Number of people receiving post-GBV care	1,000
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	263
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	737
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	331
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	24
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	155
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	37
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	5
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	34
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	179
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	9
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	44
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	139
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	4
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	94
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	250
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	7
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	9
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	1
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	2,806
OVC_SERV_DSD	Age/Sex: 10-14 Male	468



OVC_SERV_DSD	Age/Sex: 15-17 Male	444
OVC_SERV_DSD	By: Age/sex: Male 18-24	76
OVC_SERV_DSD	Age/Sex: 10-14 Female	604
OVC_SERV_DSD	Age/Sex: 15-17 Female	463
OVC_SERV_DSD	By: Age/sex: 18-24 Female	125
OVC_SERV_DSD	Sum of Age/Sex disaggregates	1,979
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	7
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	4
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	6
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	3
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	8
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	46
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	3
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	4
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	3
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	4



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	2
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	7
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	13
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	4
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	21
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	16
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	4
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	3
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	1
OVC_SERV_DSD	Age/Sex: <1	8
OVC_SERV_DSD	Age/Sex: 1-9	618
OVC_SERV_DSD	Program Completion: Active	216
OVC_SERV_DSD	Program Completion: Graduation	2,590
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	2,677
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR	2,806

	OVC programs for children and families affected by HIV/AIDS	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,178
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	37
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	435
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	48
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	627
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,856
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,285
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	571
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,856
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	37,496
TX_CURR_DSD	Age/Sex: 15-19 Male	669
TX_CURR_DSD	Age/Sex: 15-19 Female	1,080
TX_CURR_DSD	Sum of age/sex disaggregates	1,749
TX_CURR_DSD	Age/Sex: <1	208



TX_CURR_DSD	Age/Sex: <1-9	481
TX_CURR_DSD	Age/Sex: 10-14 Male	267
TX_CURR_DSD	Age/Sex: 10-14 Female	463
TX_CURR_DSD	Age/Sex: 20-24 Male	637
TX_CURR_DSD	Age/Sex: 50+ Male	2,311
TX_CURR_DSD	Age/Sex: 20-24 Female	1,886
TX_CURR_DSD	Age/Sex: 50+ Female	2,648
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	3,345
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,471
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	3,638
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	2,329
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	3,522
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	2,497
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	5,007
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	5,032
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,077
TX_NEW_DSD	By Age/Sex: 1-9	224
TX_NEW_DSD	By Age/Sex: 10-14 Male	12
TX_NEW_DSD	By Age/Sex: 15-19 Male	64
TX_NEW_DSD	By Age/Sex: 20-24 Male	36
TX_NEW_DSD	By Age/Sex: 50+ Male	738
TX_NEW_DSD	By Age/Sex: 15-19 Female	59
TX_NEW_DSD	By Age/Sex: 20-24 Female	32
TX_NEW_DSD	By Age/Sex: 50+ Female	534



TX_NEW_DSD	Sum of Age/Sex disaggregates	1,475
TX_NEW_DSD	Pregnancy status	519
TX_NEW_DSD	Breastfeeding status	517
TX_NEW_DSD	FSW	65
TX_NEW_DSD	MSM	46
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	24
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	15
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	60
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	40
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	72
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	40
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	127
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	38,894
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	628
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	14,796
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	840
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	21,016
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	9,581
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting	10,436



	period, including those who have died, those who have stopped ART, and those lost to follow-up	
TX_RET_DSD	Numerator by Status: Pregnant	1,977
TX_RET_DSD	Numerator by Status: Breastfeeding	521
TX_RET_DSD	Denominator by Status: Pregnant	2,182
TX_RET_DSD	Denominator by Status: Breastfeeding	576
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	264
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,768
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	348
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,201
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	291
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,015
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	387
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the	5,743



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
HTS_SELF_DSD	HTS_SELF_N_DSD	506
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Unassisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	15
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	15
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	19



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	15



HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	250
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	256
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	64
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	128
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	64
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	150
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	173
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	75
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	94
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	937
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	1,561
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	34
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	32
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	869
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	626
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	35
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	12
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	434



TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	456
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	1,561
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	937
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	38,147
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	1,551
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	1,169
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	21,188
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	15,330
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	38,147
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	38,147
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	38,147

Implementing Mechanism Details

Mechanism ID: 10274	Mechanism Name: MARCH Zambia
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: New Partner	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 733,451	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 733,451	
Funding Source	Funding Amount
GHP-State	733,451



Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	25,000
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Key Populations: FSW	60,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Education	40,000
Condom programming	60,000

Budget Code Information

Mechanism ID: 10274 Mechanism Name: MARCH Zambia Prime Partner Name: New Partner		
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	366,725
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	366,726

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the	12,970



	minimum components during the reporting period.	
PP_PREV_DSD	Age/sex: 10-14 Male	643
PP_PREV_DSD	Age/sex: 15-19 Male	650
PP_PREV_DSD	Age/sex: 20-24 Male	1,320
PP_PREV_DSD	Age/sex: 50+ Male	65
PP_PREV_DSD	Age/sex: 10-14 Female	650
PP_PREV_DSD	Age/sex: 15-19 Female	650
PP_PREV_DSD	Age/sex: 20-24 Female	3,084
PP_PREV_DSD	Age/sex: 50+ Female	74
PP_PREV_DSD	Sum of Age/Sex disaggregates	7,136
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	1,281
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	650
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	651
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	650
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	651
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	650
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	651
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	650
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	550
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	100
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	450
HTC_TST_DSD	Number of individuals who received T&C services for	1,244

	HIV and received their test results during the past 12 months	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	200
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	20
HTC_TST_DSD	By Key Population: FSW, Negative	661
HTC_TST_DSD	By Key Population: FSW, Positive	58
HTC_TST_DSD	By Key Population: MSM, Negative	98
HTC_TST_DSD	By Key Population: MSM, Positive	7
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	160
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	14
HTC_TST_DSD	By Key Population: TG, Negative	11
HTC_TST_DSD	By Key Population: TG, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	300
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	250
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	380
HTS_SELF_DSD	HTS_SELF_N_DSD	60
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Unassisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14,	1



	Male, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39,	3



	Female, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	32
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	28
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	7
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	14
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	7
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	16
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	8
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	11

Implementing Mechanism Details

Mechanism ID: 10984	Mechanism Name: DOD Project Concern
----------------------------	--

Approved



	International PCI
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Project Concern International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 10984		
Mechanism Name: DOD Project Concern International PCI		
Prime Partner Name: Project Concern International		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount



Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 11027	Mechanism Name: National AIDS Council Joint Financing Arrangement
Funding Agency: State/AF	Procurement Type: Cooperative Agreement
Prime Partner Name: National HIV/AIDS/STI/TB Council - Zambia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: State/AF

Total All Funding Sources: 191,583	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 191,583	
Funding Source	Funding Amount
GHP-State	191,583

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 11027		
Mechanism Name: National AIDS Council Joint Financing Arrangement		
Prime Partner Name: National HIV/AIDS/STI/TB Council - Zambia		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	191,583
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 11626	Mechanism Name: Jhpiego
Funding Agency: DOD	Procurement Type: Grant



Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 11626 Mechanism Name: Jhpiego Prime Partner Name: JHPIEGO		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 11627	Mechanism Name: DAO Lusaka
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: U.S. Department of Defense (Defense)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,328,201	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,328,201	
Funding Source	Funding Amount
GHP-State	1,328,201

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	8,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Capacity building



Gender: GBV	2,000
Focus Area:	GBV Prevention
Human Resources for Health	190,000
Motor Vehicles: Purchased	100,000
Construction	1,028,201

Budget Code Information

Mechanism ID: 11627 Mechanism Name: DAO Lusaka Prime Partner Name: U.S. Department of Defense (Defense)		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	200,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0



Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,128,201
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12272		Mechanism Name: PEPFAR OVC Small Grants	
Funding Agency: State/AF		Procurement Type: USG Core	
Prime Partner Name: U.S. Department of State			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
Global Fund / Multilateral Engagement: N/A			
G2G: No		Managing Agency:	
Total All Funding Sources: 251,500		Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 251,500			
Funding Source		Funding Amount	
GHP-State		251,500	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 12272		
Mechanism Name: PEPFAR OVC Small Grants		
Prime Partner Name: U.S. Department of State		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	251,500
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	102,769
PP_PREV_DSD	Age/sex: 10-14 Male	5,139
PP_PREV_DSD	Age/sex: 15-19 Male	5,139
PP_PREV_DSD	Age/sex: 20-24 Male	10,534
PP_PREV_DSD	Age/sex: 50+ Male	452
PP_PREV_DSD	Age/sex: 10-14 Female	5,139
PP_PREV_DSD	Age/sex: 15-19 Female	5,139
PP_PREV_DSD	Age/sex: 20-24 Female	24,664
PP_PREV_DSD	Age/sex: 50+ Female	535
PP_PREV_DSD	Sum of Age/Sex disaggregates	56,741
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	10,277



PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	5,139
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	5,121
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	5,119
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	5,139
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	5,129
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	5,052
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	5,052
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,845
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	114
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	27
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	11
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	5
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	7
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	7
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	227
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	7



HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	7
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	5
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	11
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	43
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	27
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	7
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	24
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	16
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	4



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	16
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	12
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	534
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	33
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	24
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	12
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	32
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	9
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	29
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	14
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	22
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	20
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	1



HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 1-9, Negative	147
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 1-9, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	13

HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	4



HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	1
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	8,700
OVC_SERV_DSD	Age/Sex: 10-14 Male	1,622
OVC_SERV_DSD	Age/Sex: 15-17 Male	1,619
OVC_SERV_DSD	By: Age/sex: Male 18-24	12
OVC_SERV_DSD	Age/Sex: 10-14 Female	1,981
OVC_SERV_DSD	Age/Sex: 15-17 Female	1,694
OVC_SERV_DSD	By: Age/sex: 18-24 Female	16
OVC_SERV_DSD	Sum of Age/Sex disaggregates	6,916



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	61
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	34
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	3
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	62
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	36
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	4
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	2
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	15
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	5
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	2
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	3



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	6
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	5
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	1
OVC_SERV_DSD	Age/Sex: <1	346
OVC_SERV_DSD	Age/Sex: 1-9	1,410
OVC_SERV_DSD	Program Completion: Active	1,599
OVC_SERV_DSD	Program Completion: Graduation	7,101
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	7,128
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	8,700
HTS_SELF_DSD	HTS_SELF_N_DSD	148
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Unassisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	4



	Female, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	5



	Male, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	5
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	73
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	75
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	17
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	41
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	17
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	40
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	47
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	20
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	27



	Unassisted	
--	------------	--

Implementing Mechanism Details

Mechanism ID: 13076	Mechanism Name: JSI Logistics Services
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: John Snow, Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13076		
Mechanism Name: JSI Logistics Services		
Prime Partner Name: John Snow, Inc.		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount



Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13580	Mechanism Name: CIDRZ Achieve
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: CENTER FOR INFECTIOUS DISEASE AND RESEARCH IN ZAMBIA	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 29,783,051	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 29,783,051	
Funding Source	Funding Amount
GHP-State	29,783,051

Cross-Cutting Budget Attribution(s)



Key Populations: MSM and TG	30,000
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Key Populations: FSW	50,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Condom programming	25,000
Human Resources for Health	1,201,155

Budget Code Information

Mechanism ID:	13580	
Mechanism Name:	CIDRZ Achieve	
Prime Partner Name:	CENTER FOR INFECTIOUS DISEASE AND RESEARCH IN ZAMBIA	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	1,208,926
Strategic Area	Budget Code	Planned Amount
Care	HVTB	2,600,000
Strategic Area	Budget Code	Planned Amount
Care	PDCS	1,000,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	183,403
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	795,692



Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	2,235,534
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	943,384
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	1,012,887
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	2,700,319
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	14,648,100
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	2,454,806

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	20,041
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	125,724
PMTCT_ART_DSD	New on ART	9,019
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	11,022
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	125,724



PMTCT_STAT_DSD	Number of new ANC and L&D clients	136,725
PMTCT_STAT_DSD	By Age (Denominator): 10-14	195
PMTCT_STAT_DSD	By Age (Denominator): <15-19	27,288
PMTCT_STAT_DSD	By Age (Denominator): 20-24	36,899
PMTCT_STAT_DSD	By Age (Denominator): 50+	45
PMTCT_STAT_DSD	By Number of known positives: 15-19	44
PMTCT_STAT_DSD	By Number of known positives: 20-24	2,113
PMTCT_STAT_DSD	By Number of new positives: 15-19	150
PMTCT_STAT_DSD	By Number of new positives: 20-24	2,027
PMTCT_STAT_DSD	By Number of new negative: 15-19	173
PMTCT_STAT_DSD	By Number of new negative: 20-24	22,257
PMTCT_STAT_DSD	By Age (Numerator): 15-19	367
PMTCT_STAT_DSD	By Age (Numerator): 20-24	26,401
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	31,372
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	20,463
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	20,463
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	3,000
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	27,251
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	1,995
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	3,000
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	26,816
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	1,428
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	2,396
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	16,385
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult	1,514



	35-39, Female, Newly Identified Positive	
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	469
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	12,801
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	1,905
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	32,248
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	31,249
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	20,295
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	15,164
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	32,260
VMMC_CIRC_DSD	By Age: 2 months - 9 years	8
VMMC_CIRC_DSD	By Age: 10-14	1,614
VMMC_CIRC_DSD	By Age: 15-19	12,901
VMMC_CIRC_DSD	By Age: 20-24	7,737
VMMC_CIRC_DSD	By Age: 25-29	5,160
VMMC_CIRC_DSD	By Age: 50+	344
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	22,596
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	27,756
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	32,158
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	102
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	1,615
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	1,590
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	1,291
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,172
PrEP_NEW_DSD	Female 20-24	200
PrEP_NEW_DSD	FSW	694
PrEP_NEW_DSD	MSM	150



PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	200
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	329
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	299
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	60
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	60
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	12
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	12
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	28,352
PP_PREV_DSD	Age/sex: 10-14 Male	1,353
PP_PREV_DSD	Age/sex: 15-19 Male	1,414
PP_PREV_DSD	Age/sex: 20-24 Male	2,864
PP_PREV_DSD	Age/sex: 50+ Male	145
PP_PREV_DSD	Age/sex: 10-14 Female	1,417
PP_PREV_DSD	Age/sex: 15-19 Female	1,416
PP_PREV_DSD	Age/sex: 20-24 Female	5,882
PP_PREV_DSD	Age/sex: 50+ Female	163
PP_PREV_DSD	Sum of Age/Sex disaggregates	14,654
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	2,639
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	1,448
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	1,638
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	1,581
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	1,599
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	1,581
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	1,623
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	1,589
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	3,348
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key	500



	populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,567
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	281
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	638,200
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	1,307
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	722
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	1,259
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	68
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	331
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	1,107
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24,	72



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	677
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	877
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	48
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	833
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	98
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	8,151
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	151
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	690
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	20
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	148
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	597
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	20
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	150
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	19
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	490
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	62



	20-24, Female, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	362
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	43
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	377
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	47
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	380
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	47
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	1,288
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	11,005
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	99
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	5,970
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	52
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	15,233
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	248
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	3,845
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	140
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24,	12,955



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	350
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	7,386
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	535
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	9,147
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	732
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	8,688
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	1,258
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	50,148
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	1,212
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	458
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	32
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	123
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	419
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	243
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	18



	Positive	
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	328
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	329
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	17,000
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	349
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	367
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	62
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	170
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	74
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	336
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	112
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	367
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	117
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	427
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	205
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	889
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	597



HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	1,744
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	9,703
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	95
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	9,635
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	115
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	3,192
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	698
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	375
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	2,296
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	225
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	1,046
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	188
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	2,357
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	283
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1,455
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	397



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	2,050
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	593
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	1,417
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	923
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	4,328
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	272
HTC_TST_DSD	By Key Population: FSW, Negative	2,454
HTC_TST_DSD	By Key Population: FSW, Positive	266
HTC_TST_DSD	By Key Population: MSM, Negative	173
HTC_TST_DSD	By Key Population: MSM, Positive	19
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	534
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	135
HTC_TST_DSD	By Key Population: TG, Negative	33
HTC_TST_DSD	By Key Population: TG, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	78
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	280
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	1,783
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	227



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	644
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	155
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	1,614
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	323
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	1,115
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	272
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	1,159
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	482
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	958
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	750
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	3,683
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	255
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	542
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	22,351
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	1,460
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	30,879
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	2,047
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	1,844
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	124
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	3,207



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	78
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	1,763
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	14,367
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	375
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	3,849
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	122
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	12,299
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	726
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	7,385
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	344
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	9,509
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	704
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	9,197
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	1,103
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	19,720
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	406
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	115



HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	62
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	1,683
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	68
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	516
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	32
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	1,552
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	142
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	777
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	68
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	1,164
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	91
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	1,036
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	91
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 1-9, Negative	737
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 1-9, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Negative	107



HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Negative	53
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Negative	991
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Negative	263
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	678
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative	882
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	523
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	500
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Negative	542
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Negative	500
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Positive	8



HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative	542
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Negative	500
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Negative	542
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative	500
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	542
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Negative	713
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Negative	699
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	1,402
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	462
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	1,293



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	631
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	1,380
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	462
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	1,303
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	631
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	1,380
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	462
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	1,293
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	631
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	1,390
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	462
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	1,293
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	631
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	614
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	642
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	80



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	614
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	642
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	614
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	642
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	614
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	642
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	284
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	293
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	65
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	304



HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	293
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	49
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	284
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	54
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	313
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	49
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	284
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	293
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	49
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	868
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	173
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	936
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	310
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	937
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	374



HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	936
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	310
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	977
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	403
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	936
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	310
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	937
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	445
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	936
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	310
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	967
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	374
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	7,003
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	548
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	7,017
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	1,073
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	7,003



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	548
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	7,017
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	1,073
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	7,003
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	548
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	7,017
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	1,073
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	7,003
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	548
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	7,017
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	1,073
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	230
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	253
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	230
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Positive	24



HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	253
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	230
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	253
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	230
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	253
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	21,383
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	1,434
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	16,042
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	1,075
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	10,699
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	716
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	5,344



HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	350
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Female, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Female, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Male, Negative	79
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	965
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	55
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	239
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	827
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	56
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	415
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	82
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	438
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	445
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	68



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	428
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	445
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	428
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	445
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	428
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	445
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	593
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	566
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	110
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	318



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	154
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	331
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	171
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	318
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	154
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	331
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	171
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	318
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	154
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	331
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	171
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	318
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	154
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	331
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	171
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	7,016
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	518



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	7,305
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	750
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	7,016
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	518
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	7,305
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	750
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	7,016
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	518
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	7,305
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	750
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	7,016
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	518
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	7,305
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	750
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Negative	777
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Negative	777



HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Positive	91
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Negative	777
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Positive	78
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	777
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Positive	101
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	777
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	777
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	113
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	777
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Positive	68
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	777
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	91
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	2,107
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	2,107
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	20



HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	2,107
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	2,107
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	20
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	13,321
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	13,321
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	261
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8,482
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	207
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4,371
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	261
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	8,482
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	207
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	4,371



	during the reporting period)	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	7,316
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	256
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,707
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	335
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3,972
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	20,041
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	16,025
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	4,016
PMTCT_EID_DSD	Sum of Infant Age disaggregates	20,041
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	318,876
TX_CURR_DSD	Age/Sex: 15-19 Male	5,277
TX_CURR_DSD	Age/Sex: 15-19 Female	7,438
TX_CURR_DSD	Sum of age/sex disaggregates	12,715
TX_CURR_DSD	Age/Sex: <1	4,256
TX_CURR_DSD	Age/Sex: <1-9	8,345



TX_CURR_DSD	Age/Sex: 10-14 Male	2,229
TX_CURR_DSD	Age/Sex: 10-14 Female	3,908
TX_CURR_DSD	Age/Sex: 20-24 Male	5,279
TX_CURR_DSD	Age/Sex: 50+ Male	18,176
TX_CURR_DSD	Age/Sex: 20-24 Female	16,546
TX_CURR_DSD	Age/Sex: 50+ Female	25,310
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	25,633
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	9,883
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	29,554
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	16,480
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	29,634
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	23,232
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	41,507
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	46,189
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	45,516
TX_NEW_DSD	By Age/Sex: <1	44
TX_NEW_DSD	By Age/Sex: 1-9	3,361
TX_NEW_DSD	By Age/Sex: 10-14 Male	617
TX_NEW_DSD	By Age/Sex: 15-19 Male	1,441
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,377
TX_NEW_DSD	By Age/Sex: 50+ Male	8,594
TX_NEW_DSD	By Age/Sex: 10-14 Female	254
TX_NEW_DSD	By Age/Sex: 15-19 Female	1,007
TX_NEW_DSD	By Age/Sex: 20-24 Female	926



TX_NEW_DSD	By Age/Sex: 50+ Female	5,757
TX_NEW_DSD	Sum of Age/Sex disaggregates	19,973
TX_NEW_DSD	Pregnancy status	6,746
TX_NEW_DSD	Breastfeeding status	10,884
TX_NEW_DSD	FSW	718
TX_NEW_DSD	MSM	554
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,926
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,264
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	2,309
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,883
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	2,541
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	2,727
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	3,941
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	5,547
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	317,074
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	8,598
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	124,447
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	10,770
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	173,479
TX_RET_DSD	Number of adults and children who are still alive and on	83,042



	treatment at 12 months after initiating ART	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	91,095
TX_RET_DSD	Numerator by Status: Pregnant	17,521
TX_RET_DSD	Numerator by Status: Breastfeeding	4,627
TX_RET_DSD	Denominator by Status: Pregnant	19,149
TX_RET_DSD	Denominator by Status: Breastfeeding	5,050
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,181
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	32,175
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,913
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	45,773
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,363
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	35,195
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	3,160



	stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	50,377
HTS_SELF_DSD	HTS_SELF_N_DSD	67,908
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	672
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Unassisted	1,343
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	672
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	1,343
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	2,017
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	2,017
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	1,343
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	1,343
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	2,689
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	2,688
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	2,689
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	2,689
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	2,689
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29,	2,689



	Female, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	2,689
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	2,689
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	2,689
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	2,689
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	2,689
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	2,689
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	2,689
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	2,689
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	2,689
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	2,689
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	2,689
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	2,689
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	2,689
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	2,687
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	672
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	665
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male,	672



	Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	686
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	33,624
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	34,284
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	8,572
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	17,140
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	8,572
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	20,159
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	22,698
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	10,082
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	12,911
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	24,199
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	40,597
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	1,141
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	970
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	23,233
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	15,253



TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	908
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	304
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	11,195
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	11,792
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	40,597
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	24,199
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	317,836
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	12,714
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	9,533
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	171,629
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	123,960
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	317,836
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	317,836
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	317,836

Implementing Mechanism Details

Mechanism ID: 14339	Mechanism Name: PEPFAR Prevention Small Grants
Funding Agency: State/AF	Procurement Type: Grant
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 48,500	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 48,500	
Funding Source	Funding Amount
GHP-State	48,500

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 14339		
Mechanism Name: PEPFAR Prevention Small Grants		
Prime Partner Name: U.S. Department of State		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	48,500
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14420	Mechanism Name: LPHO Follow On
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Lusaka Provincial Health Office	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 4,031,175	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 4,031,175	
Funding Source	Funding Amount
GHP-State	4,031,175

Cross-Cutting Budget Attribution(s)

Human Resources for Health	2,200,000
----------------------------	-----------

Budget Code Information

Mechanism ID: 14420		
Mechanism Name: LPHO Follow On		
Prime Partner Name: Lusaka Provincial Health Office		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	699,713



Strategic Area	Budget Code	Planned Amount
Care	HVTB	195,920
Strategic Area	Budget Code	Planned Amount
Care	PDCS	55,977
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	75,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	187,878
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	600,000
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	197,222
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,946,266
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	73,199

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	17,300
VMMC_CIRC_DSD	By Age: 2 months - 9 years	6
VMMC_CIRC_DSD	By Age: 10-14	867



VMMC_CIRC_DSD	By Age: 15-19	6,922
VMMC_CIRC_DSD	By Age: 20-24	4,167
VMMC_CIRC_DSD	By Age: 25-29	2,769
VMMC_CIRC_DSD	By Age: 50+	165
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	12,121
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	14,890
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	17,245
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	55
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	866
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	849
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	689
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	17,368
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	917
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	5,138
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	52
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	5,138
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	58
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	1,714
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	1,070
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	1,070
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	11



HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	1,070
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	1,070
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	11

Implementing Mechanism Details

Mechanism ID: 14421	Mechanism Name: SPMO Follow On
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Southern Provincial Health Office	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 2,583,161	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,583,161	
Funding Source	Funding Amount
GHP-State	2,583,161

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 14421



Mechanism Name: SPMO Follow On		
Prime Partner Name: Southern Provincial Health Office		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	743,658
Strategic Area	Budget Code	Planned Amount
Care	HVTB	152,806
Strategic Area	Budget Code	Planned Amount
Care	PDCS	40,748
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	75,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	156,521
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	650,000
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	364,075
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	306,558
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	93,795

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
-------------------------	--------------	-------------



VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	23,900
VMMC_CIRC_DSD	By Age: 10-14	1,186
VMMC_CIRC_DSD	By Age: 15-19	9,480
VMMC_CIRC_DSD	By Age: 20-24	5,775
VMMC_CIRC_DSD	By Age: 25-29	3,905
VMMC_CIRC_DSD	By Age: 50+	246
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	16,687
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	20,592
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	23,824
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	76
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	1,186
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	1,183
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	939
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	24,191
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	1,424
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	7,041
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	73
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	7,130
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	74
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	2,345
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	1,505
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	11



HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	1,505
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	1,505
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	1,505
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	11

Implementing Mechanism Details

Mechanism ID: 14452	Mechanism Name: Society for Family Health
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 745,628	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 262,191	
Total All Funding Sources and Applied Pipeline Amount: 1,007,819	
Funding Source	Funding Amount
GHP-State	745,628

Cross-Cutting Budget Attribution(s)

Gender: GBV	2,500
Focus Area:	GBV Prevention
Sub Area:	Capacity building



Gender: Gender Equality	2,500
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Human Resources for Health	40,628

Budget Code Information

Mechanism ID: 14452		
Mechanism Name: Society for Family Health		
Prime Partner Name: Population Services International		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount



Prevention	CIRC	745,628
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	29,961
VMMC_CIRC_DSD	By Age: 10-14	1,498
VMMC_CIRC_DSD	By Age: 15-19	11,984
VMMC_CIRC_DSD	By Age: 20-24	7,191
VMMC_CIRC_DSD	By Age: 25-29	4,794
VMMC_CIRC_DSD	By Age: 50+	300
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	20,973
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	25,767
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	29,961
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	1,498
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	1,498
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	1,198
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	29,970
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	1,494
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	8,961
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	8,961
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	2,987
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	1,867



HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	1,867
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	1,867
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	1,867
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	6

Implementing Mechanism Details

Mechanism ID: 14507	Mechanism Name: Family Health International
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 14507 Mechanism Name: Family Health International Prime Partner Name: FHI 360		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,129
PMTCT_ART_DSD	Number of pregnant women with known HIV status	13,988



	(includes women who were tested for HIV and received their results)	
PMTCT_ART_DSD	New on ART	1,361
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	768
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	13,988
PMTCT_STAT_DSD	Number of new ANC and L&D clients	14,735
PMTCT_STAT_DSD	By Age (Denominator): 10-14	139
PMTCT_STAT_DSD	By Age (Denominator): <15-19	2,446
PMTCT_STAT_DSD	By Age (Denominator): 20-24	4,015
PMTCT_STAT_DSD	By Age (Denominator): 50+	482
PMTCT_STAT_DSD	By Number of known positives: 20-24	263
PMTCT_STAT_DSD	By Number of new positives: 15-19	139
PMTCT_STAT_DSD	By Number of new positives: 20-24	305
PMTCT_STAT_DSD	By Number of new positives: 50+	37
PMTCT_STAT_DSD	By Number of new negative: 20-24	1,878
PMTCT_STAT_DSD	By Age (Numerator): 15-19	139
PMTCT_STAT_DSD	By Age (Numerator): 20-24	2,446
PMTCT_STAT_DSD	By Age (Numerator): 50+	147
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	2,502
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	2,502
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	2,502
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	147
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	165
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	3,396
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	189
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	165
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult	2,258



	30-34, Female, Newly Identified Negative	
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	189
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	165
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	2,148
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	189
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	10
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	2,179
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	313
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	3,750
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	2,502
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	2,502
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	2,502
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	27,853
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	54
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	48
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	3



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	29
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	38
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	36
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	666
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	168
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	565
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	310
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	400
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	379



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	56
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	45
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	36
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	72
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	54
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	46
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	96
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	85
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	25
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female,	88



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	44
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	71
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	41
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	70
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	2,865
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	3,958
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	236
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	622
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	167
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	535
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	321
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	15



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	413
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	400
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	48
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Negative	42
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Negative	11
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative	37
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	22
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	22
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Negative	23
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Negative	22
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative	23
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39,	22



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Negative	23
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative	22
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	23
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Negative	30
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Negative	30
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	41
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	37
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	41
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	37
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	41



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	37
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	41
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	37
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	26
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	28
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	26
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	28
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	26
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	3



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	28
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	26
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	28
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	306
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	307
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	306
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	307
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	306
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	307



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	306
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	307
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	2,741
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	2,056
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	1,371
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	685
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	40
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	11
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	35
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	19
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	4



	Positive	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	19
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	20
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	19
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	20
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	19
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	20
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	19
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	20
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female,	26



	Negative	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	68
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	68
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	68
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	68
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49,	14



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	65
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	305
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	317
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	305
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	317
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	305
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	317
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	305
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	317

	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	33
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,106
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,106
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	55
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	532
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	88
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	431
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	55
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	532
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	88
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	431
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	553
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The	19



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	209
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	25
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	300
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,129
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,703
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	426
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,129
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	45,968
TX_CURR_DSD	Age/Sex: 15-19 Male	460
TX_CURR_DSD	Age/Sex: 15-19 Female	647
TX_CURR_DSD	Sum of age/sex disaggregates	1,107
TX_CURR_DSD	Age/Sex: 20-24 Male	941
TX_CURR_DSD	Age/Sex: 50+ Male	3,673
TX_CURR_DSD	Age/Sex: 20-24 Female	1,839
TX_CURR_DSD	Age/Sex: 50+ Female	4,071
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	2,838
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male,	1,888



	Positive	
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	3,605
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,065
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	4,406
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	3,067
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	8,708
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	8,760
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,000
TX_NEW_DSD	By Age/Sex: 15-19 Male	227
TX_NEW_DSD	By Age/Sex: 20-24 Male	299
TX_NEW_DSD	By Age/Sex: 50+ Male	1,200
TX_NEW_DSD	By Age/Sex: 15-19 Female	232
TX_NEW_DSD	By Age/Sex: 50+ Female	1,100
TX_NEW_DSD	Sum of Age/Sex disaggregates	3,058
TX_NEW_DSD	Pregnancy status	1,332
TX_NEW_DSD	Breastfeeding status	1,332
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	207
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	117
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	413
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	1,205
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	45,968



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	19,854
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	26,114
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,064
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,515
TX_RET_DSD	Numerator by Status: Pregnant	896
TX_RET_DSD	Numerator by Status: Breastfeeding	236
TX_RET_DSD	Denominator by Status: Pregnant	995
TX_RET_DSD	Denominator by Status: Breastfeeding	262
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,707
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,357
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,896
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,619
HTS_SELF_DSD	HTS_SELF_N_DSD	879
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	9
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14,	18



	Female, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	9
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	18
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	26
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	26
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	18
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	18
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	35



	Male, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	35
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	9
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	9
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	9
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	479
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	400
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	112
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	225
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted -	112



	Sex Partner	
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	15,951
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	31,903
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	472
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	314
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	17,602
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	13,515
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	236
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	157
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	8,800
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	6,758
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	31,903
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	15,951
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	32,258
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	1,290
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	968
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	17,419
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	12,581
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	32,258
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of	32,258



	Specimen Sent]: Gene Xpert MTB / R if Assay	
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	32,258

Implementing Mechanism Details

Mechanism ID: 16634	Mechanism Name: USAID/Copperbelt Lusaka Zambia Family activity
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Expanded Church Response Trust	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 7,893,213	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 7,893,213	
Funding Source	Funding Amount
GHP-State	7,893,213

Cross-Cutting Budget Attribution(s)

Gender: GBV	450,000
Focus Area:	Post GBV Care
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Food and Nutrition: Policy, Tools, and Service Delivery	500,000
Adolescent Girls and Young Women (AGYW)	3,753,924
Water	350,000



Economic Strengthening	900,000
Education	500,000

Budget Code Information

Mechanism ID: 16634		
Mechanism Name: USAID/Copperbelt Lusaka Zambia Family activity		
Prime Partner Name: Expanded Church Response Trust		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	636,095
Strategic Area	Budget Code	Planned Amount
Care	HKID	4,916,030
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	587,164
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	1,176,679
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	577,245
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	24,262
PP_PREV_DSD	Age/sex: 10-14 Male	1,081
PP_PREV_DSD	Age/sex: 15-19 Male	711
PP_PREV_DSD	Age/sex: 20-24 Male	5,018
PP_PREV_DSD	Age/sex: 50+ Male	76
PP_PREV_DSD	Age/sex: 10-14 Female	1,092
PP_PREV_DSD	Age/sex: 15-19 Female	994
PP_PREV_DSD	Age/sex: 20-24 Female	5,377
PP_PREV_DSD	Age/sex: 50+ Female	85
PP_PREV_DSD	Sum of Age/Sex disaggregates	14,434
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	2,184
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	1,092
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	1,092
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	1,092
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	1,092
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	1,092
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	1,092
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	1,092
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,954
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	10
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	10
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	7



	20-24, Female, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	5
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	19
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	22
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	25
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	56
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19,	38



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	56
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	35
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	75
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	39
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	65
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	38
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	64
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	40
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	61
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	43
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	77
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	30
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19,	9



	Male, Negative	
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	27
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	14
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	19
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	17
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 1-9, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	4



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	61
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	61
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	61
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	61
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	61
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	61
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	61
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	61
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29,	3



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	1



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	1
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	89,578
OVC_SERV_DSD	Age/Sex: 10-14 Male	18,601
OVC_SERV_DSD	Age/Sex: 15-17 Male	15,923
OVC_SERV_DSD	By: Age/sex: Male 18-24	2,116
OVC_SERV_DSD	Age/Sex: 10-14 Female	15,467
OVC_SERV_DSD	Age/Sex: 15-17 Female	18,223
OVC_SERV_DSD	By: Age/sex: 18-24 Female	2,865
OVC_SERV_DSD	Sum of Age/Sex disaggregates	68,214
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	55
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	41
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	3
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	65
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	38
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	3



	and sex: Education Support Male 18-24	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	2,047
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	1,982
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	1,723
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	1,697
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	2,023
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	1,976
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	1,619
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	1,410
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	1,295
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	1,252
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	1,426
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	1,285
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	1,596
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	1,336
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	1,967
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	1,899
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	1,879



	and sex: Economic Strengthening Female 18-24	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	1,953
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	1,893
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	1,876
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	1,667
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	1,644
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	1,600
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	1,621
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	1,615
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	1,601
OVC_SERV_DSD	Age/Sex: <1	2,327
OVC_SERV_DSD	Age/Sex: 1-9	14,056
OVC_SERV_DSD	Program Completion: Active	8,314
OVC_SERV_DSD	Program Completion: Graduation	81,264
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	9,715
OVC_SERV_TA	Age/Sex: 10-14 Male	1,400
OVC_SERV_TA	Age/Sex: 15-17 Male	1,400
OVC_SERV_TA	By age/sex: 18-24 Male	1,201
OVC_SERV_TA	By age/sex: 25+ Male	410
OVC_SERV_TA	Age/Sex: 10-14 Female	1,400
OVC_SERV_TA	Age/Sex: 15-17 Female	1,400
OVC_SERV_TA	By age/sex: 18-24 Female	1,207



OVC_SERV_TA	By age/sex: 25+ Female	1,297
OVC_SERV_TA	Sum of Age/Sex disaggregates	5,600
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 10-14	1,100
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 15-17	1,200
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 18-24	1,007
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 25+	1,097
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 10-14	1,100
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 15-17	1,200
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 18-24	1,001
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 25+	610
OVC_SERV_TA	Program Completion: Graduated	9,715
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	80,037
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	89,578
HTS_SELF_DSD	HTS_SELF_N_DSD	90
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Unassisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19,	2



	Female, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	1
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	4



	Female, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	2
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	3
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	46
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	11
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	22
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	11
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	25
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	29
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	12
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	17

Implementing Mechanism Details

Mechanism ID: 17396	Mechanism Name: Sexual and Reproductive
----------------------------	--



	Health for All Initiative (SARAI)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Society for Family Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 400,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 400,000	
Funding Source	Funding Amount
GHP-State	400,000

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	71,429
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Adolescent Girls and Young Women (AGYW)	71,429
Food and Nutrition: Policy, Tools, and Service Delivery	71,429
Human Resources for Health	71,428
Condom programming	71,429
Water	71,427

Budget Code Information



Mechanism ID: 17396		
Mechanism Name: Sexual and Reproductive Health for All Initiative (SARAI)		
Prime Partner Name: Society for Family Health		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	350,000
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	50,000
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	5,637
PP_PREV_DSD	Age/sex: 10-14 Male	219
PP_PREV_DSD	Age/sex: 15-19 Male	219
PP_PREV_DSD	Age/sex: 20-24 Male	435
PP_PREV_DSD	Age/sex: 50+ Male	22



PP_PREV_DSD	Age/sex: 10-14 Female	219
PP_PREV_DSD	Age/sex: 15-19 Female	219
PP_PREV_DSD	Age/sex: 20-24 Female	1,055
PP_PREV_DSD	Age/sex: 50+ Female	25
PP_PREV_DSD	Sum of Age/Sex disaggregates	2,413
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	439
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	257
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	219
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	580
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	219
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	580
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	219
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	711
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	134
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	6
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24,	1



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	14
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	3



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 1-9, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	2



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	3
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	6,829
OVC_SERV_DSD	Age/Sex: 10-14 Male	1,058
OVC_SERV_DSD	Age/Sex: 15-17 Male	1,095
OVC_SERV_DSD	By: Age/sex: Male 18-24	186
OVC_SERV_DSD	Age/Sex: 10-14 Female	1,202



OVC_SERV_DSD	Age/Sex: 15-17 Female	1,442
OVC_SERV_DSD	By: Age/sex: 18-24 Female	316
OVC_SERV_DSD	Sum of Age/Sex disaggregates	4,797
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	9
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	8
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	11
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	6
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	23
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	13
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	5
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	26
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	19
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	12
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	3
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	3
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	60
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	60
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	50



	and sex: Social Protection Female 18-24	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	60
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	60
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	50
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	69
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	15
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	60
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	66
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	58
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	8
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	17
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	11
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	4
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	3
OVC_SERV_DSD	Age/Sex: <1	44
OVC_SERV_DSD	Age/Sex: 1-9	1,486
OVC_SERV_DSD	Program Completion: Active	424
OVC_SERV_DSD	Program Completion: Graduation	6,405
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	5,656



OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	6,829
-----------------	---	-------

Implementing Mechanism Details

Mechanism ID: 17399	Mechanism Name: USAID/District Coverage of Health Services (DISCOVER-H)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow Inc (JSI)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 19,903,870	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 19,903,870	
Funding Source	Funding Amount
GHP-State	19,903,870

Cross-Cutting Budget Attribution(s)

Adolescent Girls and Young Women (AGYW)	2,500,000
Human Resources for Health	400,000
Condom programming	500,000

Budget Code Information

Mechanism ID: 17399		
Mechanism Name: USAID/District Coverage of Health Services (DISCOVER-H)		
Prime Partner Name: John Snow Inc (JSI)		
Strategic Area	Budget Code	Planned Amount



Care	HBHC	2,162,543
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	810,954
Strategic Area	Budget Code	Planned Amount
Care	PDCS	946,112
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	1,000,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	140,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	2,770,095
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,621,906



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	1,574,230
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	503,654
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	7,968,899
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	405,477

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,458
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	18,042
PMTCT_ART_DSD	New on ART	1,359
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,099
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	18,042



PMTCT_STAT_DSD	Number of new ANC and L&D clients	18,073
PMTCT_STAT_DSD	By Age (Denominator): 10-14	27
PMTCT_STAT_DSD	By Age (Denominator): <15-19	3,715
PMTCT_STAT_DSD	By Age (Denominator): 20-24	5,454
PMTCT_STAT_DSD	By Age (Denominator): 50+	2
PMTCT_STAT_DSD	By Number of known positives: 15-19	4
PMTCT_STAT_DSD	By Number of known positives: 20-24	213
PMTCT_STAT_DSD	By Number of new positives: 15-19	23
PMTCT_STAT_DSD	By Number of new positives: 20-24	287
PMTCT_STAT_DSD	By Number of new negative: 20-24	3,216
PMTCT_STAT_DSD	By Age (Numerator): 15-19	27
PMTCT_STAT_DSD	By Age (Numerator): 20-24	3,715
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	3,486
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	2,705
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	2,684
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	299
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	4,835
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	287
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	299
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	2,983
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	205
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	238
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	2,247
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	220

PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	46
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	2,300
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	338
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	5,421
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	3,486
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	2,705
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	2,684
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	35,048
VMMC_CIRC_DSD	By Age: 0-60 days	2
VMMC_CIRC_DSD	By Age: 2 months - 9 years	3
VMMC_CIRC_DSD	By Age: 10-14	1,734
VMMC_CIRC_DSD	By Age: 15-19	13,927
VMMC_CIRC_DSD	By Age: 20-24	8,396
VMMC_CIRC_DSD	By Age: 25-29	5,626
VMMC_CIRC_DSD	By Age: 50+	391
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	24,448
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	30,074
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	34,648
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	1,774
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	1,771
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	1,424
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	2,133
PrEP_NEW_DSD	Female 20-24	353
PrEP_NEW_DSD	FSW	1,215
PrEP_NEW_DSD	MSM	268
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	354



PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	634
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	529
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	108
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	108
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	23
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	24
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	55,003
PP_PREV_DSD	Age/sex: 10-14 Male	2,458
PP_PREV_DSD	Age/sex: 15-19 Male	2,890
PP_PREV_DSD	Age/sex: 20-24 Male	6,925
PP_PREV_DSD	Age/sex: 50+ Male	268
PP_PREV_DSD	Age/sex: 10-14 Female	2,466
PP_PREV_DSD	Age/sex: 15-19 Female	2,897
PP_PREV_DSD	Age/sex: 20-24 Female	12,472
PP_PREV_DSD	Age/sex: 50+ Female	270
PP_PREV_DSD	Sum of Age/Sex disaggregates	30,646
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	4,896
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	2,974
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	3,028
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	2,736
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	2,687
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	2,687
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	2,679
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	2,670
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	8,035
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV	8,035



	preventive interventions that are based on evidence and/or meet the minimum standards required)	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	164,174
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	311
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	170
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	159
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	39
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	144
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	89
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	114
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male,	110



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	1,930
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	34
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	503
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	114
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	336
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	84
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	277
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	28
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	165
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	215
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	219



	50+, Male, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	22
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	1,017
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	2,605
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	1,412
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	2,001
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	507
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	1,699
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	10,934
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	1,428
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	1,203
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	102



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,141
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	168
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	11,883
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	286
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	230
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	60
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	212
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	122
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	165
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	165
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	4,025



HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	81
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	29
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	2,011
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	11,251
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	111
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	11,251
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	141
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	3,666



HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	46
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	168
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	92
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	280
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	117
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	286
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	168
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	45
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	242
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	66
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	158
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	111
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	1,026



HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	65
HTC_TST_DSD	By Key Population: MSM, Positive	1
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	10,000
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	1,359
HTC_TST_DSD	By Key Population: TG, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	67
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	200
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	1,015
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	173
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	417
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	117
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	936
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	217
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	672
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	187
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	656
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+,	286



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	541
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	420
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	2,509
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	173
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	61
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	2,582
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	202
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	3,567
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	282
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	213
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	784
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	435
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	1,914
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	45
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	505
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	14



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	1,609
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	99
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	967
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	43
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	1,243
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	95
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	1,204
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	145
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	4,821
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	97
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	104
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	57
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	999
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	33
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	306
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	922
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	68



HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	462
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	33
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	691
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	44
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	615
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	44
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 1-9, Negative	645
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 1-9, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Negative	126
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Negative	32
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	160
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative	113
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Positive	1



HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	65
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	61
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Negative	67
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Negative	61
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative	67
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Negative	61
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Negative	67
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative	61
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	67
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Positive	1



HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Negative	93
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Negative	93
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	159
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	149
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	72
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	159
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	149
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	72
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	159
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	149
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	72
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	159
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	50



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	149
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	72
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	79
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	83
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	79
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	83
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	79
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	83
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	79
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	83



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	160
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	165
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	160
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	175
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	160
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	165
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	180
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	165
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	24

HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	177
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	591
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	208
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	589
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	244
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	588
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	208
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	587
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	244
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	569
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	213
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	558
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	244
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	564
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	205
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	555



HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	245
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	923
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	75
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	924
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	141
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	923
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	75
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	924
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	141
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	923
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	75
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	924
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	141
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	923
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	75
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	924
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	141



HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	114
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	127
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	114
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	127
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	114
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	127
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	114
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	127
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	2,473



HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	197
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	1,853
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	150
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	1,236
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	97
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	616
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	48
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Female, Negative	31
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Male, Negative	30
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	122
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	31
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	108
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	6



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	54
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	55
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	58
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	55
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	58
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	55
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	58
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	55
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	58



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	79
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	77
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	6



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	917
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	66
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	956
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	103
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	917
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	66
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	956
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	103
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	917
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	66
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	956
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	103
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	917



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	66
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	956
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	103
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Negative	462
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Negative	462
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Positive	54
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Negative	462
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	462
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	462
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	462
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	49
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	462
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Positive	33

HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	462
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	2,485
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	2,485
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	2,485
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	2,485
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	23
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	439
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	439
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	283
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	6
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number	142



	of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	8
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	283
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	6
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	142
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	247
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	8
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	95
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	10
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	134
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,458



PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,965
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	493
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,458
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	46,268
TX_CURR_DSD	Age/Sex: 15-19 Male	681
TX_CURR_DSD	Age/Sex: 15-19 Female	1,346
TX_CURR_DSD	Sum of age/sex disaggregates	2,027
TX_CURR_DSD	Age/Sex: <1	636
TX_CURR_DSD	Age/Sex: <1-9	1,221
TX_CURR_DSD	Age/Sex: 10-14 Male	166
TX_CURR_DSD	Age/Sex: 10-14 Female	569
TX_CURR_DSD	Age/Sex: 20-24 Male	892
TX_CURR_DSD	Age/Sex: 50+ Male	2,769
TX_CURR_DSD	Age/Sex: 20-24 Female	2,761
TX_CURR_DSD	Age/Sex: 50+ Female	3,125
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	3,428
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,810
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	4,531
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	2,919
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	4,114
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	2,842
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	5,762
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male,	6,687



	Positive	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	14,386
TX_NEW_DSD	By Age/Sex: <1	5
TX_NEW_DSD	By Age/Sex: 1-9	480
TX_NEW_DSD	By Age/Sex: 10-14 Male	18
TX_NEW_DSD	By Age/Sex: 15-19 Male	143
TX_NEW_DSD	By Age/Sex: 20-24 Male	221
TX_NEW_DSD	By Age/Sex: 50+ Male	1,932
TX_NEW_DSD	By Age/Sex: 10-14 Female	151
TX_NEW_DSD	By Age/Sex: 15-19 Female	134
TX_NEW_DSD	By Age/Sex: 20-24 Female	475
TX_NEW_DSD	By Age/Sex: 50+ Female	793
TX_NEW_DSD	Sum of Age/Sex disaggregates	3,867
TX_NEW_DSD	Pregnancy status	288
TX_NEW_DSD	Breastfeeding status	1,585
TX_NEW_DSD	FSW	587
TX_NEW_DSD	MSM	542
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	932
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	682
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	1,316
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	916
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	1,194
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	867
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	2,041
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	2,086



	Positive	
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	44,655
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,299
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	17,673
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,784
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	23,899
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	9,068
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	10,473
TX_RET_DSD	Numerator by Status: Pregnant	1,745
TX_RET_DSD	Numerator by Status: Breastfeeding	465
TX_RET_DSD	Denominator by Status: Pregnant	2,002
TX_RET_DSD	Denominator by Status: Breastfeeding	518
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	409
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,537
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	532
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,590



TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	456
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,199
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	602
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,216
HTS_SELF_DSD	HTS_SELF_N_DSD	20,323
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	200
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Unassisted	399
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	201
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	399
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	600
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	598
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	401



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	399
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	803
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	796
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	803
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	798
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	803
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	803
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	803
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	803
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	803
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	803
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	803
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	803
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	803
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	803
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	803
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	803



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	803
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	801
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	803
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	799
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	200
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	196
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	200
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	244
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	10,076
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	10,247
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	2,561
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	5,125
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	2,561
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	6,030
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	6,657
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	3,019
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	3,696
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of	2,913

	Isoniazid Preventive Therapy (IPT) during the reporting period	
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	4,855
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	149
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	144
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	2,660
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	1,902
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	109
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	41
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	1,342
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,421
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	4,855
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	2,913
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	45,305
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	1,884
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	1,433
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	24,370
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	17,618
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	45,305
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	45,305
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	45,305



Implementing Mechanism Details

Mechanism ID: 17400	Mechanism Name: Eradicate TB
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Program for Appropriate Technology in Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 1,860,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,860,000	
Funding Source	Funding Amount
GHP-State	1,860,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	260,000
Renovation	218,878
Motor Vehicles: Purchased	40,000

Budget Code Information

Mechanism ID:	17400	
Mechanism Name:	Eradicate TB	
Prime Partner Name:	Program for Appropriate Technology in Health	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	1,860,000
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	6,446
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	308
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	50
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	146
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	62
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	284
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	99



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	308
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	100
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	363
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	174
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	755
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	501
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	269
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	131
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	275
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	149
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	269
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	131
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	275
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	149
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	269
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	131
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	275



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	149
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	269
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	131
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	275
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	149
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	9,979
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	9,979
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	471
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5,742
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	403
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,363
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	471
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	5,742
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	403



TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3,363
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	5,250
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	178
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,985
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	233
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,852

Implementing Mechanism Details

Mechanism ID: 17403	Mechanism Name: Gender Based Violence - Survivor Support Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: World Vision International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17403		
Mechanism Name: Gender Based Violence - Survivor Support Project		
Prime Partner Name: World Vision International		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 17410	Mechanism Name: USAID/Zambia Community HIV Prevention Project (Z-CHPP)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Pact	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 15,066,954	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 15,066,954	
Funding Source	Funding Amount
GHP-State	15,066,954

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	1,561,075
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Economic Strengthening	711,075
Human Resources for Health	819,638
Adolescent Girls and Young Women (AGYW)	8,909,686
Condom programming	725,000

Budget Code Information

Mechanism ID:	17410
Mechanism Name:	USAID/Zambia Community HIV Prevention Project (Z-CHPP)
Prime Partner Name:	Pact



Strategic Area	Budget Code	Planned Amount
Care	HBHC	799,473
Strategic Area	Budget Code	Planned Amount
Care	HKID	6,562,859
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	2,950,031
Strategic Area	Budget Code	Planned Amount



Prevention	HVCT	2,593,876
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	2,160,715
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	304,419
PP_PREV_DSD	Age/sex: 10-14 Male	15,176
PP_PREV_DSD	Age/sex: 15-19 Male	16,023
PP_PREV_DSD	Age/sex: 20-24 Male	28,233
PP_PREV_DSD	Age/sex: 50+ Male	1,495
PP_PREV_DSD	Age/sex: 10-14 Female	15,321
PP_PREV_DSD	Age/sex: 15-19 Female	16,022
PP_PREV_DSD	Age/sex: 20-24 Female	73,540



PP_PREV_DSD	Age/sex: 50+ Female	1,559
PP_PREV_DSD	Sum of Age/Sex disaggregates	167,369
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	30,420
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	15,289
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	15,321
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	15,311
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	15,311
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	15,297
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	15,260
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	14,841
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	31,024
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	684
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	158
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	296
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	72
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	243
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	28



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	143
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	191
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	192
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	23
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	1,361
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	27
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	202
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	55
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	184
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	105
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	142



HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	144
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	82
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	28
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	301
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	37
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	900
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	199
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	406
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	158
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	863
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	240
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	617
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	204
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	711
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	317



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	505
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	408
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	3,344
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	260
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	145
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	76
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	871
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	31
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	268
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	805
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	59
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	402
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	31
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	605



HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	39
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	536
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	39
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 1-9, Negative	880
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 1-9, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	139
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	144
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	139
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	144
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	139
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	144
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	24

HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	139
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	144
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	556
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	243
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	557
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	261
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	567
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	248
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	549
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	266
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	555
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	253
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	567
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	271
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	605



HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	238
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	567
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	261
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	100
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	113
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	100
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	113
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	100
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	113
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	100
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	9



HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	113
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Negative	402
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Negative	402
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Negative	402
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	402
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	402
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	402
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	402
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	402



HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	39
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	109,034
OVC_SERV_DSD	Age/Sex: 10-14 Male	22,958
OVC_SERV_DSD	Age/Sex: 15-17 Male	21,508
OVC_SERV_DSD	By: Age/sex: Male 18-24	2,598
OVC_SERV_DSD	Age/Sex: 10-14 Female	22,501
OVC_SERV_DSD	Age/Sex: 15-17 Female	21,944
OVC_SERV_DSD	By: Age/sex: 18-24 Female	4,768
OVC_SERV_DSD	Sum of Age/Sex disaggregates	88,911
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	709
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	464
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	229
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	578
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	478
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	185
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	1,926
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	1,801
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	265
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	745
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	1,897



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	1,840
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	133
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	51
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	1,741
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	1,220
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	742
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	1,616
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	1,185
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	624
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	2,364
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	1,575
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	986
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	2,002
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	1,498
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	197
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	368
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	265



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	8
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	82
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	57
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	9
OVC_SERV_DSD	Age/Sex: <1	804
OVC_SERV_DSD	Age/Sex: 1-9	11,953
OVC_SERV_DSD	Program Completion: Active	21,593
OVC_SERV_DSD	Program Completion: Graduation	87,441
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	83,576
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	109,034
HTS_SELF_DSD	HTS_SELF_N_DSD	8,057
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	78
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Unassisted	158
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	78
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	158
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	237
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	237
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	158
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	158



	Male, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	319
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	318
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	319
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	318
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	319
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	318
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	319
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	319
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	319
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	319
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	319
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	319
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	319
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	319
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	319
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	319
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49,	319



	Female, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	319
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	319
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	312
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	78
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	73
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	78
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	98
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	3,995
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	4,062
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	1,015
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	2,032
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	1,015
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	2,387
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	2,784
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	1,192
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	1,592

Implementing Mechanism Details

Mechanism ID: 17413	Mechanism Name: SAFE
----------------------------	-----------------------------



Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: John Snow Inc (JSI)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 24,553,204	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 103,279	
Total All Funding Sources and Applied Pipeline Amount: 24,656,483	
Funding Source	Funding Amount
GHP-State	24,553,204

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17413		
Mechanism Name: SAFE		
Prime Partner Name: John Snow Inc (JSI)		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	2,324,259
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	248,298
Strategic Area	Budget Code	Planned Amount



Care	PDCS	2,069,154
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	579,357
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	555,900
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	370,821
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	2,909,262
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,086,212
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	600,000
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	3,136,546



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	8,024,879
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	2,648,516

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	14,596
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	109,794
PMTCT_ART_DSD	New on ART	8,135
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	6,461
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	109,794
PMTCT_STAT_DSD	Number of new ANC and L&D clients	111,912
PMTCT_STAT_DSD	By Age (Denominator): 10-14	153
PMTCT_STAT_DSD	By Age (Denominator): <15-19	22,656
PMTCT_STAT_DSD	By Age (Denominator): 20-24	33,890
PMTCT_STAT_DSD	By Age (Denominator): 50+	28
PMTCT_STAT_DSD	By Number of known positives: 15-19	18
PMTCT_STAT_DSD	By Number of known positives: 20-24	1,249
PMTCT_STAT_DSD	By Number of new positives: 15-19	128



PMTCT_STAT_DSD	By Number of new positives: 20-24	1,813
PMTCT_STAT_DSD	By Number of new positives: 50+	9
PMTCT_STAT_DSD	By Number of new negative: 15-19	7
PMTCT_STAT_DSD	By Number of new negative: 20-24	19,523
PMTCT_STAT_DSD	By Number of new negative: 50+	74
PMTCT_STAT_DSD	By Age (Numerator): 15-19	153
PMTCT_STAT_DSD	By Age (Numerator): 20-24	22,586
PMTCT_STAT_DSD	By Age (Numerator): 50+	83
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	21,624
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	16,739
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	16,739
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	83
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	1,760
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	29,730
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	1,803
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	1,760
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	18,586
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	1,288
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	1,403
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	13,925
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	1,138
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	262
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult	13,362



	40-49, Female, Newly Identified Negative	
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	1,956
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	33,313
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	21,624
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	16,466
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	15,569
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	57,681
VMMC_CIRC_DSD	By Age: 0-60 days	2
VMMC_CIRC_DSD	By Age: 2 months - 9 years	3
VMMC_CIRC_DSD	By Age: 10-14	2,885
VMMC_CIRC_DSD	By Age: 15-19	22,833
VMMC_CIRC_DSD	By Age: 20-24	13,712
VMMC_CIRC_DSD	By Age: 25-29	9,525
VMMC_CIRC_DSD	By Age: 50+	624
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	40,054
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	49,579
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	57,460
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	2,896
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	2,876
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	2,325
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,732
PrEP_NEW_DSD	Female 20-24	284
PrEP_NEW_DSD	FSW	984
PrEP_NEW_DSD	MSM	213
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	290
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	519
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	430



PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	87
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	82
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	19
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	21
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	521,409
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	1,668
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	42
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	909
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	760
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	43
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	194
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	669
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	409
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	535
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	27



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	513
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	61
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	10,317
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	186
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	143
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	34
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	90
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	24
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	75
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	45
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	59
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	59



	50+, Male, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	283
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	13,924
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	120
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	7,541
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	61
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	9,432
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	161
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	2,398
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	93
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	8,006
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	192
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	4,396
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	332
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	5,652
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	464



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	5,379
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	794
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	63,500
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	1,542
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	62
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	18
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	57
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	33
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	45
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	45
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	21,506



HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	429
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	3,024
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	16,566
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	162
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	16,322
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	189
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	5,395
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	70
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	892
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	51
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	481
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	23



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	1,616
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	161
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	885
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	158
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	1,633
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	228
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1,093
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	310
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	1,433
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	433
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	1,078
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	616
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	5,586
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	350
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	15
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	52
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	3



	Male, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	237
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	26
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	64
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	242
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	38
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	135
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	31
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	137
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	57
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	104
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	93
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	665
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	42
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	485
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	19,648
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	1,316
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	27,160



HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	1,837
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	1,625
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	112
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	4,191
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	94
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	2,310
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	8,899
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	221
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	2,369
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	70
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	7,617
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	440
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	4,579
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	213
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	5,887
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	441
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	5,672
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	677



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	25,888
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	534
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	30
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	16
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	270
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	83
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	249
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	125
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	186
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	166
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 1-9, Negative	184
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 1-9, Positive	4



	Positive	
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Negative	122
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Negative	63
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Negative	592
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Negative	148
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	846
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative	533
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	316
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	306
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Negative	325
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34,	306



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative	325
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Negative	306
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Negative	325
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative	306
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	325
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Negative	421
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Negative	419
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	1,098
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	360
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29,	1,032



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	457
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	1,081
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	360
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	1,037
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	457
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	1,079
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	360
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	1,030
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	457
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	1,080
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	360
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	1,030
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	457
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	372
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	37
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	388
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	47



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	372
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	37
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	388
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	372
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	37
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	388
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	372
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	37
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	388
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	43
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	45
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34,	43



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	45
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	43
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	45
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	43
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	45
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	976
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	220
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	108
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	108
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	40



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	108
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	108
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	108
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	108
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	108
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	108
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	4,353
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	342
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	4,355
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	666
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34,	4,353



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	342
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	4,355
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	666
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	4,353
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	342
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	4,355
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	666
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	4,353
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	342
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	4,355
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	666
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	31
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	33
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	31
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	3



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	33
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	31
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	33
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	31
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	33
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	18,804
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	1,278
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	14,100
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	965
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	9,381
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	641
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49,	4,718



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	317
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Female, Negative	153
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Female, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Male, Negative	109
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	568
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	139
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	502
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	255
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	263
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	278
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	42



	Positive	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	263
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	278
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	263
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	278
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	263
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	278
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	370
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	354
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	76
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29,	6



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	4,345
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	317
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	4,505
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	468
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	4,410
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	317



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	4,505
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	468
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	4,319
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	317
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	4,565
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	468
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	4,319
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	317
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	4,505
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	468
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Negative	125
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Negative	125
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Negative	125
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	125



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	125
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	125
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	125
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	125
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	3,779
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	3,779
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	3,779
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	3,779
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	32



	Male, Positive	
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	263
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	263
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	9
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	149
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	6
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	99
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	9
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	149
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	6
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	99
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	142
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	3



	TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	54
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	5
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	77
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	14,596
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	11,672
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	2,924
PMTCT_EID_DSD	Sum of Infant Age disaggregates	14,596
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	302,832
TX_CURR_DSD	Age/Sex: 15-19 Male	3,368
TX_CURR_DSD	Age/Sex: 15-19 Female	8,360
TX_CURR_DSD	Sum of age/sex disaggregates	11,728
TX_CURR_DSD	Age/Sex: <1	3,611
TX_CURR_DSD	Age/Sex: <1-9	10,429
TX_CURR_DSD	Age/Sex: 10-14 Male	993
TX_CURR_DSD	Age/Sex: 10-14 Female	3,872
TX_CURR_DSD	Age/Sex: 20-24 Male	5,594
TX_CURR_DSD	Age/Sex: 50+ Male	16,391
TX_CURR_DSD	Age/Sex: 20-24 Female	20,352
TX_CURR_DSD	Age/Sex: 50+ Female	20,029
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29,	22,101



	Female, Positive	
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	12,858
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	28,507
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	19,338
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	26,928
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	17,947
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	38,987
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	43,167
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	57,153
TX_NEW_DSD	By Age/Sex: <1	33
TX_NEW_DSD	By Age/Sex: 1-9	1,541
TX_NEW_DSD	By Age/Sex: 10-14 Male	482
TX_NEW_DSD	By Age/Sex: 15-19 Male	1,491
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,327
TX_NEW_DSD	By Age/Sex: 50+ Male	5,719
TX_NEW_DSD	By Age/Sex: 10-14 Female	589
TX_NEW_DSD	By Age/Sex: 15-19 Female	1,029
TX_NEW_DSD	By Age/Sex: 20-24 Female	2,010
TX_NEW_DSD	By Age/Sex: 50+ Female	2,804
TX_NEW_DSD	Sum of Age/Sex disaggregates	15,451
TX_NEW_DSD	Pregnancy status	2,514
TX_NEW_DSD	Breastfeeding status	6,846
TX_NEW_DSD	FSW	1,179
TX_NEW_DSD	MSM	1,157
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29,	3,588



	Female, Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	3,191
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	4,899
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	3,954
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	4,516
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	3,681
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	7,639
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	8,625
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	302,778
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	9,218
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	118,427
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	9,432
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	165,690
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	59,258
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	69,099
TX_RET_DSD	Numerator by Status: Pregnant	12,264
TX_RET_DSD	Numerator by Status: Breastfeeding	3,234



TX_RET_DSD	Denominator by Status: Pregnant	13,466
TX_RET_DSD	Denominator by Status: Breastfeeding	3,554
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,247
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	21,497
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,960
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	32,554
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,517
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	27,832
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,322
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	35,428
HTS_SELF_DSD	HTS_SELF_N_DSD	91,660



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	901
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Unassisted	1,800
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	901
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	1,800
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	2,702
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	2,703
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	1,803
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	1,802
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	3,601
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	3,603
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	3,603
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	3,603
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	3,603
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	3,603
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	3,603
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	3,603
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	3,603



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	3,603
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	3,603
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	3,667
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	3,603
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	3,903
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	3,603
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	3,903
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	3,603
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	3,603
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	3,603
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	3,603
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	903
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	894
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	899
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	915
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	45,052
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	46,608
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	11,652



HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	23,304
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	11,652
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	27,026
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	29,980
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	13,518
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	16,622
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	20,764
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	34,562
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	1,246
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	1,035
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	18,605
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	13,613
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	780
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	274
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	9,622
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	10,088
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	34,499
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT,	20,764



	Life-long ART, New, Positive	
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	302,906
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	12,129
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	9,096
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	163,430
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	118,251
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	302,906
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	302,906
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	302,906

Implementing Mechanism Details

Mechanism ID: 17422	Mechanism Name: USAID Open Doors
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,516,060	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,516,060	
Funding Source	Funding Amount
GHP-State	3,516,060

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	1,214,969
-----------------------------	-----------



Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Key Populations: FSW	1,073,747
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Gender: Gender Equality	170,653
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Focus Area:	Equity in HIV prevention, care, treatment and support

Budget Code Information

Mechanism ID: 17422 Mechanism Name: USAID Open Doors Prime Partner Name: FHI 360		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	1,055,876
Strategic Area	Budget Code	Planned Amount
Care	HKID	400,000
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0



Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	353,657
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	1,706,527
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount



Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	17,456
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,542
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	300
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	12,614
HTC_TST_DSD	Number of individuals who received T&C services for	15,168



	HIV and received their test results during the past 12 months	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	12,083
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	1,599
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	1,393
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	93
HTC_TST_DSD	By Key Population: FSW, Negative	11,825
HTC_TST_DSD	By Key Population: FSW, Positive	1,566
HTC_TST_DSD	By Key Population: MSM, Negative	1,393
HTC_TST_DSD	By Key Population: MSM, Positive	93
HTC_TST_DSD	By Key Population: TG, Negative	258
HTC_TST_DSD	By Key Population: TG, Positive	33
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	7,793
OVC_SERV_DSD	Age/Sex: 10-14 Male	1,134
OVC_SERV_DSD	Age/Sex: 15-17 Male	1,770
OVC_SERV_DSD	By: Age/sex: Male 18-24	248
OVC_SERV_DSD	Age/Sex: 10-14 Female	1,180
OVC_SERV_DSD	Age/Sex: 15-17 Female	1,768
OVC_SERV_DSD	By: Age/sex: 18-24 Female	362
OVC_SERV_DSD	Sum of Age/Sex disaggregates	5,852
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	54
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	25
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	3
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	54



	and sex: Education Support Male 10-14	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	27
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	2
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	196
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	100
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	26
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	46
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	181
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	102
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	18
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	3
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	140
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	101
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	48
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	151
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	89
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	42
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	248



	and sex: Economic Strengthening Female 10-14	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	102
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	58
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	215
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	88
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	52
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	21
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	16
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	4
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	3
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	1
OVC_SERV_DSD	Age/Sex: <1	15
OVC_SERV_DSD	Age/Sex: 1-9	1,316
OVC_SERV_DSD	Program Completion: Active	7,793
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	7,382
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	7,793
HTS_SELF_DSD	HTS_SELF_N_DSD	1,820
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14,	18



	Female, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Unassisted	36
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	18
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	36
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	54
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	54
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	36
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	36
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	72
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	72
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	72
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	72
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	72
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	72
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	72
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	72
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	72
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	72



	Female, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	72
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	72
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	72
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	72
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	72
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	72
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	72
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	72
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	72
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	71
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	18
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	15
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	18
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	21
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	903
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	917
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	229
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted -	459



	Self	
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	229
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	538
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	627
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	269
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	358

Implementing Mechanism Details

Mechanism ID: 17425	Mechanism Name: USAID Systems for Better Health
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,771,091	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,771,091	
Funding Source	Funding Amount
GHP-State	2,771,091

Cross-Cutting Budget Attribution(s)

Human Resources for Health	600,000
----------------------------	---------



Budget Code Information

Mechanism ID: 17425 Mechanism Name: USAID Systems for Better Health Prime Partner Name: Abt Associates		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	350,081
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	900,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,311,261
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	209,749

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17478	Mechanism Name: CLSI
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Clinical and Laboratory Standards Institute	

Approved



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,236,046	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,236,046	
Funding Source	Funding Amount
GHP-State	1,236,046

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17478	
Mechanism Name:	CLSI	
Prime Partner Name:	Clinical and Laboratory Standards Institute	
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	1,236,046

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17479	Mechanism Name: APHL
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	

Approved



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 750,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 750,000	
Funding Source	Funding Amount
GHP-State	750,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17479	
Mechanism Name:	APHL	
Prime Partner Name:	Association of Public Health Laboratories	
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	750,000

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17497	Mechanism Name: University of Maryland SMACHT
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: University of Maryland	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 14,984,205	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 14,984,205	
Funding Source	Funding Amount
GHP-State	14,984,205

Cross-Cutting Budget Attribution(s)

Key Populations: FSW	50,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	30,000
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Condom programming	25,000
Human Resources for Health	2,953,174



Budget Code Information

Mechanism ID: 17497 Mechanism Name: University of Maryland SMACHT Prime Partner Name: University of Maryland		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	400,000
Strategic Area	Budget Code	Planned Amount
Care	HVTB	500,000
Strategic Area	Budget Code	Planned Amount
Care	PDCS	1,000,000
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	556,348
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	639,790
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	1,450,000
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	8,945,560
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	1,492,507

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
------------------	-------	------



PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	5,761
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	50,218
PMTCT_ART_DSD	New on ART	2,818
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,943
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	50,218
PMTCT_STAT_DSD	Number of new ANC and L&D clients	52,750
PMTCT_STAT_DSD	By Age (Denominator): 10-14	69
PMTCT_STAT_DSD	By Age (Denominator): <15-19	10,562
PMTCT_STAT_DSD	By Age (Denominator): 20-24	15,421
PMTCT_STAT_DSD	By Age (Denominator): 50+	14
PMTCT_STAT_DSD	By Number of known positives: 15-19	34
PMTCT_STAT_DSD	By Number of known positives: 20-24	561
PMTCT_STAT_DSD	By Number of new positives: 15-19	58
PMTCT_STAT_DSD	By Number of new positives: 20-24	516
PMTCT_STAT_DSD	By Number of new negative: 15-19	66
PMTCT_STAT_DSD	By Number of new negative: 20-24	9,247
PMTCT_STAT_DSD	By Age (Numerator): 15-19	158
PMTCT_STAT_DSD	By Age (Numerator): 20-24	10,324
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	10,898
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	7,893
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	7,893
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	795
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	13,034
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	522



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	795
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	9,731
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	372
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	634
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	6,736
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	523
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	124
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	5,643
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	827
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	14,351
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	10,898
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	7,893
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	6,594
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,689
PrEP_NEW_DSD	Female 20-24	280
PrEP_NEW_DSD	FSW	978
PrEP_NEW_DSD	MSM	211
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	280
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	506
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	421
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	84
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	84



PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	17
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	17
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	721
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	100
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	621
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	315,052
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	435
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	234
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	902
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	52
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	238
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	22



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	791
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	55
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	483
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	629
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	600
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	74
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	2,673
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	46
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	133
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	31
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	171
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	44
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	140



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	83
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	109
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	111
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	266
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	3,606
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	1,957
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	11,117
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	183
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	2,808
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	105



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	9,426
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	242
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	5,177
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	388
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	6,669
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	551
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	6,333
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	941
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	16,460
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	401
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	116
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	31
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	107
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	61



HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	83
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	84
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	5,576
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	114
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	53
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	24
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	52
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	53
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	61
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	42
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	126



HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	118
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	252
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	140
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	1,387
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	119
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	540
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	95
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	1,434
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	142
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	818
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	255
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	1,275
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	374
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	800
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	653
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	1,561



HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	100
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	11
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	37
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	384
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	69
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	128
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	52
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	342
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	86
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	223
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	76
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	247
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	112
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	192
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	158
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9,	480



	Negative	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	224
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	9,209
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	378
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	12,726
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	525
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	760
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	1,081
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	603
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	10,389
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	301
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	2,797
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	100
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	8,929
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	519
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	5,359



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	284
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	6,896
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	561
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	6,674
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	876
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	6,675
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	152
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	29
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	14
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	508
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	156
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	469
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	40
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	234
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	351

HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	313
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 1-9, Negative	172
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 1-9, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Negative	32
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Negative	698
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Negative	189
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	217
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative	623
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	374
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Positive	1



HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	355
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Negative	388
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Negative	355
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative	388
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Negative	355
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Negative	388
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative	355
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	388
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Negative	494



HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Negative	496
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	709
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	268
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	728
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	408
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	709
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	268
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	728
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	408
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	709
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	268
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	728
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	418
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	709
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	268



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	728
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	428
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	441
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	463
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	441
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	463
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	441
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	463
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	441
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	50
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	463



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	82
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	85
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	82
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	85
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	82
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	85
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	82
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	85
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	13

HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	272
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	57
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	187
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	83
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	188
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	95
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	187
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	83
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	188
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	95
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	187
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	83
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	188
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	110
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	187
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	83
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	188



HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	95
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	5,116
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	410
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	5,126
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	783
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	5,116
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	410
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	5,126
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	783
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	5,116
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	410
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	5,126
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	783
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	5,116
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	410
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	5,126
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	783



HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	58
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	64
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	58
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	64
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	58
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	64
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	58
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	64
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	8,815

HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	371
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	6,608
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	278
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	4,405
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	178
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	2,203
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	94
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Female, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Male, Negative	11
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	400
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	81
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	274
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	17



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	146
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	148
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	155
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	148
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	155
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	148
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	155
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	148
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	155



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	203
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	195
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	45
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	49
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	45
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	49
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	45
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	49
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	34

HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	45
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	49
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	5,093
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	387
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	5,301
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	551
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	5,193
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	387
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	5,301
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	551
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	5,093
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	387
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	5,401
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	551
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	5,093



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	387
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	5,301
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	551
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Negative	234
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Negative	234
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Negative	234
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	234
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	234
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	234
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	234
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Positive	17



HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	234
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	24
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,966
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,966
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	53
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,160
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	55
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	698
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	53
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,160
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	55
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	698
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,145



TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	40
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	405
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	52
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	623
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	5,761
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	4,603
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,158
PMTCT_EID_DSD	Sum of Infant Age disaggregates	5,761
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	119,579
TX_CURR_DSD	Age/Sex: 15-19 Male	3,319
TX_CURR_DSD	Age/Sex: 15-19 Female	3,352
TX_CURR_DSD	Sum of age/sex disaggregates	6,671
TX_CURR_DSD	Age/Sex: <1	2,815
TX_CURR_DSD	Age/Sex: <1-9	5,157
TX_CURR_DSD	Age/Sex: 10-14 Male	1,034
TX_CURR_DSD	Age/Sex: 10-14 Female	2,796
TX_CURR_DSD	Age/Sex: 20-24 Male	3,137
TX_CURR_DSD	Age/Sex: 50+ Male	7,627



TX_CURR_DSD	Age/Sex: 20-24 Female	5,515
TX_CURR_DSD	Age/Sex: 50+ Female	6,338
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	8,559
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	3,739
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	10,803
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	7,360
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	9,653
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	8,569
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	15,245
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	14,699
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	28,104
TX_NEW_DSD	By Age/Sex: <1	32
TX_NEW_DSD	By Age/Sex: 1-9	3,011
TX_NEW_DSD	By Age/Sex: 10-14 Male	179
TX_NEW_DSD	By Age/Sex: 15-19 Male	388
TX_NEW_DSD	By Age/Sex: 20-24 Male	488
TX_NEW_DSD	By Age/Sex: 50+ Male	3,044
TX_NEW_DSD	By Age/Sex: 10-14 Female	497
TX_NEW_DSD	By Age/Sex: 15-19 Female	759
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,194
TX_NEW_DSD	By Age/Sex: 50+ Female	2,097
TX_NEW_DSD	Sum of Age/Sex disaggregates	8,646
TX_NEW_DSD	Pregnancy status	3,971
TX_NEW_DSD	Breastfeeding status	7,005



TX_NEW_DSD	FSW	446
TX_NEW_DSD	MSM	917
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,994
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	645
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	2,461
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,333
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	2,232
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,561
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	3,576
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	2,613
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	119,719
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	5,085
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	48,445
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	6,747
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	59,442
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	22,918
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	24,197



	stopped ART, and those lost to follow-up	
TX_RET_DSD	Numerator by Status: Pregnant	4,768
TX_RET_DSD	Numerator by Status: Breastfeeding	1,255
TX_RET_DSD	Denominator by Status: Pregnant	5,022
TX_RET_DSD	Denominator by Status: Breastfeeding	1,320
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	870
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,358
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,155
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	12,535
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	927
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,839
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,229
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	13,202



	including those who have died, those who have stopped ART, and those lost to follow-up)	
HTS_SELF_DSD	HTS_SELF_N_DSD	47,392
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	459
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Unassisted	918
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	459
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	918
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	1,378
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	1,378
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	918
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	918
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	1,836
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	1,836
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	1,836
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	1,836
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	1,836
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	1,836
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	1,836
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	2,036



	Male, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	1,836
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	2,036
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	1,836
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	2,036
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	1,836
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	2,036
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	1,836
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	2,036
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	1,836
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	1,836
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	1,836
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	1,836
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	459
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	458
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	459
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	475
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	22,967

HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	24,425
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	6,106
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	12,213
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	6,106
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	13,778
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	15,910
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	6,888
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	8,828
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	22,226
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	37,045
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	935
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	728
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	23,449
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	11,933
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	838
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	305
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	10,254
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	10,829



TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	37,045
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	22,226
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	108,945
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	4,357
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	3,269
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	58,829
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	42,490
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	108,945
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	108,945
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	108,945

Implementing Mechanism Details

Mechanism ID: 17499	Mechanism Name: TDRC
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Tropical Diseases Research Centre	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 1,274,868	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,274,868	
Funding Source	Funding Amount
GHP-State	1,274,868



Cross-Cutting Budget Attribution(s)

Human Resources for Health	400,000
----------------------------	---------

Budget Code Information

Mechanism ID: 17499		
Mechanism Name: TDRRC		
Prime Partner Name: Tropical Diseases Research Centre		
Strategic Area	Budget Code	Planned Amount
Care	HVTB	50,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	600,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	100,000
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	524,868

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17513	Mechanism Name: Ministry of Health
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health, Zambia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC
Total All Funding Sources: 1,955,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,955,000	
Funding Source	Funding Amount
GHP-State	1,955,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17513		
Mechanism Name: Ministry of Health		
Prime Partner Name: Ministry of Health, Zambia		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	79,200
Strategic Area	Budget Code	Planned Amount
Care	HVTB	250,800
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	100,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	800,000
Strategic Area	Budget Code	Planned Amount

Approved



Prevention	CIRC	300,000
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	300,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	125,000

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17514	Mechanism Name: Jhpiego Follow-On
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Johns Hopkins University Bloomberg School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,950,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,950,000	
Funding Source	Funding Amount
GHP-State	3,950,000

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	17514	
Mechanism Name:	Jhpiego Follow-On	
Prime Partner Name:	Johns Hopkins University Bloomberg School of Public Health	
Strategic Area	Budget Code	Planned Amount
Care	HVTB	248,500
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	3,600,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	101,500

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	66,384
VMMC_CIRC_DSD	By Age: 2 months - 9 years	19
VMMC_CIRC_DSD	By Age: 10-14	3,365
VMMC_CIRC_DSD	By Age: 15-19	25,905
VMMC_CIRC_DSD	By Age: 20-24	15,502
VMMC_CIRC_DSD	By Age: 25-29	10,919
VMMC_CIRC_DSD	By Age: 50+	1,047
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	45,819
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	56,738
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	63,794
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	89
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	3,368
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	3,339



VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	2,920
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	63,086
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	3,245
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	18,355
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	179
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	18,355
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	192
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	5,995
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	75
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	4,132
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	4,132
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	4,132
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	4,132
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	34

Implementing Mechanism Details

Mechanism ID: 17788	Mechanism Name: USAID/South-Central Zambia
----------------------------	---



	Family Activity
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Development Aid from People to People Humana Zambia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 7,172,253	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 7,172,253	
Funding Source	Funding Amount
GHP-State	7,172,253

Cross-Cutting Budget Attribution(s)

Education	300,000
Water	300,000
Human Resources for Health	2,200,000
Food and Nutrition: Commodities	2,086,127
Economic Strengthening	2,386,127

Budget Code Information

Mechanism ID: 17788		
Mechanism Name: USAID/South-Central Zambia Family Activity		
Prime Partner Name: Development Aid from People to People Humana Zambia		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	1,000,000
Strategic Area	Budget Code	Planned Amount



Care	HKID	5,072,253
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	600,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	500,000
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	106,336
OVC_SERV_DSD	Age/Sex: 10-14 Male	20,039
OVC_SERV_DSD	Age/Sex: 15-17 Male	17,004
OVC_SERV_DSD	By: Age/sex: Male 18-24	2,142
OVC_SERV_DSD	Age/Sex: 10-14 Female	21,723
OVC_SERV_DSD	Age/Sex: 15-17 Female	21,929
OVC_SERV_DSD	By: Age/sex: 18-24 Female	3,451
OVC_SERV_DSD	Sum of Age/Sex disaggregates	80,695
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	1,381
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	549



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	51
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	1,440
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	616
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	57
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	1,947
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	1,328
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	94
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	1,898
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	1,399
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	98
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	3,869
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	2,157
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	970
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	3,432
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	1,712
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	895
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	2,851



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	2,522
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	2,148
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	2,536
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	2,397
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	1,614
OVC_SERV_DSD	Age/Sex: <1	3,433
OVC_SERV_DSD	Age/Sex: 1-9	16,615
OVC_SERV_DSD	Program Completion: Active	94,209
OVC_SERV_DSD	Program Completion: Graduation	12,127
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	103,544
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	106,336

Implementing Mechanism Details

Mechanism ID: 17873	Mechanism Name: Health Improvement Partnership Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health, Zambia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: USAID

Total All Funding Sources: 3,000,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,000,000	



Funding Source	Funding Amount
GHP-State	3,000,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17873		
Mechanism Name: Health Improvement Partnership Project		
Prime Partner Name: Ministry of Health, Zambia		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0



Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	3,000,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18159	Mechanism Name: Global Health Supply Chain Program
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 99,482,465	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 99,482,465	
Funding Source	Funding Amount
GHP-State	74,482,465
GHP-USAID	25,000,000

Cross-Cutting Budget Attribution(s)

Condom procurement	9,113,505
--------------------	-----------

Budget Code Information

Mechanism ID:	18159	
Mechanism Name:	Global Health Supply Chain Program	
Prime Partner Name:	Global Health Supply Chain Program	
Strategic Area	Budget Code	Planned Amount



Care	HBHC	2,566,231
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	1,130,909
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	58,506,547
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	33,550,900
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	3,727,878

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18160	Mechanism Name: AIDSFree ZAMBIA
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: John Snow Inc (JSI)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 5,261,316	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 34,762	



Total All Funding Sources and Applied Pipeline Amount: 5,296,078	
Funding Source	Funding Amount
GHP-State	5,261,316

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18160		
Mechanism Name: AIDSFree ZAMBIA		
Prime Partner Name: John Snow Inc (JSI)		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	1,031,979
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	OHSS	500,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	2,731,105
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	998,232



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18161	Mechanism Name: USAID GHSC-RTK
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Remote Medical International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 4,615,500	
Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 4,615,500	
Funding Source	Funding Amount
GHP-State	4,615,500

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18161		
Mechanism Name: USAID GHSC-RTK		
Prime Partner Name: Remote Medical International		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount



Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	4,615,500
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18263	Mechanism Name: Cash Plus Care
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: UNICEF	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,200,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,200,000	
Funding Source	Funding Amount
GHP-State	2,200,000



Cross-Cutting Budget Attribution(s)

Gender: GBV	200,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Economic Strengthening	50,000
Education	400,000
Adolescent Girls and Young Women (AGYW)	150,000

Budget Code Information

Mechanism ID: 18263		
Mechanism Name: Cash Plus Care		
Prime Partner Name: UNICEF		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	2,100,000
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	100,000
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	12,184
OVC_SERV_DSD	Age/Sex: 10-14 Male	2,111
OVC_SERV_DSD	Age/Sex: 15-17 Male	1,518
OVC_SERV_DSD	By: Age/sex: Male 18-24	32
OVC_SERV_DSD	Age/Sex: 10-14 Female	2,694
OVC_SERV_DSD	Age/Sex: 15-17 Female	1,823
OVC_SERV_DSD	By: Age/sex: 18-24 Female	52
OVC_SERV_DSD	Sum of Age/Sex disaggregates	8,146
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	2
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	6
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	4
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	5



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	3
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	5
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	2
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	4
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	2
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	7
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	5
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	2
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	1
OVC_SERV_DSD	Age/Sex: 1-9	3,954
OVC_SERV_DSD	Program Completion: Active	9,809



OVC_SERV_DSD	Program Completion: Graduation	2,375
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	11,286
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	12,184
HTS_SELF_DSD	HTS_SELF_N_DSD	2,423
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	24
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Unassisted	48
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	24
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	48
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	72
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	72
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	48
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	48
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	96
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	96
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	96
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	96
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	96



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	96
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	96
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	96
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	96
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	96
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	96
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	96
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	96
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	96
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	96
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	96
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	96
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	96
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	96
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	96
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	24
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	23



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	24
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	24
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	1,200
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	1,223
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	306
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	611
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	306
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	719
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	839
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	360
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	479

Implementing Mechanism Details

Mechanism ID: 18278	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18297	Mechanism Name: UNAIDS
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: World Health Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	

Approved



G2G: No	Managing Agency:
Total All Funding Sources: 200,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 200,000	
Funding Source	Funding Amount
GHP-State	200,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18297		
Mechanism Name: UNAIDS		
Prime Partner Name: World Health Organization		
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	200,000

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18304	Mechanism Name: EQUIP
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Right To Care, South Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	

Approved



G2G: No	Managing Agency:
Total All Funding Sources: 18,905,802	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 18,905,802	
Funding Source	Funding Amount
GHP-State	18,905,802

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18304		
Mechanism Name: EQUIP		
Prime Partner Name: Right To Care, South Africa		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	4,701,760
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	569,501
Strategic Area	Budget Code	Planned Amount
Care	PDCS	118,310
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	696,245



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	325,601
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	2,150,552
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	784,864
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	600,000
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	2,091,030
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXS	4,756,374
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	2,111,565

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	4,757
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	56,803
PMTCT_ART_DSD	New on ART	3,197
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,560
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	56,803
PMTCT_STAT_DSD	Number of new ANC and L&D clients	57,409
PMTCT_STAT_DSD	By Age (Denominator): 10-14	81
PMTCT_STAT_DSD	By Age (Denominator): <15-19	11,474
PMTCT_STAT_DSD	By Age (Denominator): 20-24	15,962
PMTCT_STAT_DSD	By Age (Denominator): 50+	19
PMTCT_STAT_DSD	By Number of known positives: 15-19	6
PMTCT_STAT_DSD	By Number of known positives: 20-24	302
PMTCT_STAT_DSD	By Number of new positives: 15-19	50
PMTCT_STAT_DSD	By Number of new positives: 20-24	621
PMTCT_STAT_DSD	By Number of new negative: 15-19	25
PMTCT_STAT_DSD	By Number of new negative: 20-24	10,500
PMTCT_STAT_DSD	By Age (Numerator): 15-19	81
PMTCT_STAT_DSD	By Age (Numerator): 20-24	11,423



PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	12,685
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	8,594
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	8,594
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	429
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	14,669
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	617
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	429
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	11,695
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	442
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	336
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	7,754
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	388
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	58
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	7,403
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	1,079
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	15,715
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	12,566
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	8,478
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	8,540
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	50,971



VMMC_CIRC_DSD	By Age: 2 months - 9 years	10
VMMC_CIRC_DSD	By Age: 10-14	2,549
VMMC_CIRC_DSD	By Age: 15-19	20,391
VMMC_CIRC_DSD	By Age: 20-24	12,226
VMMC_CIRC_DSD	By Age: 25-29	8,154
VMMC_CIRC_DSD	By Age: 50+	508
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	35,674
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	43,828
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	50,971
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	2,549
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	2,548
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	2,036
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	436
PrEP_NEW_DSD	Female 20-24	72
PrEP_NEW_DSD	FSW	251
PrEP_NEW_DSD	MSM	56
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	72
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	130
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	109
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	22
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	22
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	4
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	5
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	742,719
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	846
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male,	461



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	1,978
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	117
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	509
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	45
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	1,741
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	114
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	1,064
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	36
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	1,382
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	77
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	1,312
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	152
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	5,213
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	99
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	698
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	148



	10-14, Male, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	1,121
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	34
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	277
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	31
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	910
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	112
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	541
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	58
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	716
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	77
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	721
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	90
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	1,285
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	7,033
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14,	63



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	3,814
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	24,402
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	408
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	6,170
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	231
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	20,699
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	527
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	11,366
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	847
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	14,649
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	1,204
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	13,900
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	2,068
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	32,088
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	781
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19,	759



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	57
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	205
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	696
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	26
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	400
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	30
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	541
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Positive	26
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	543
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	10,871
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	225
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female,	1



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	2,864
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	15,131
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	154
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	15,235
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	155
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	5,043
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	64
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	452
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	247
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	3,284
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	254
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	1,178
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	206
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	3,404
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	314



HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1,806
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	513
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	2,539
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	769
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	1,584
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	1,226
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	2,774
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	185
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	66
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	237
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	2,902
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	343
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	1,016
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	176
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	2,854
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	487



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	1,847
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	395
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	1,744
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	744
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	1,592
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	1,187
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	3,024
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	189
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	266
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	10,611
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	445
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	14,661
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	624
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	873
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	36
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	2,115
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	50
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	1,170
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	22,969



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	591
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	6,137
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	196
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	19,612
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	1,168
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	11,759
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	567
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	15,225
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	1,134
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	14,656
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	1,769
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	13,018
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	267
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	134
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	72
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	3,283
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	122



HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	1,011
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	57
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	3,028
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	227
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	1,516
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	114
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	2,272
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	151
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	2,019
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	151
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 1-9, Negative	831
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 1-9, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Negative	68
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Negative	36
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Negative	1,535
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Negative	414



HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	436
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative	1,362
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	822
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	786
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Negative	847
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Negative	786
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative	847
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Negative	786
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Positive	18

HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Negative	847
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative	786
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	847
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Negative	1,094
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Negative	1,090
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	1,657
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	568
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	1,512
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	849
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	1,647
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	568
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	1,482



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	859
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	1,631
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	556
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	1,452
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	859
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	1,647
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	578
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	1,502
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	859
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	968
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	111
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	1,016
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	135
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	968
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	111
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	1,016
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	135



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	968
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	111
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	1,016
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	135
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	968
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	111
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	1,016
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	135
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	529
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	57
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	593
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	91
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	529
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	57
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	594
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	93
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	529



HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	57
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	543
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	81
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	529
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	77
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	543
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	81
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	456
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	109
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	1,603
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	462
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	1,497
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	645
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	1,493
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	486
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	1,467
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	584

HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	1,527
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	462
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	1,590
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	522
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	1,473
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	474
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	1,457
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	584
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	11,236
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	894
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	11,258
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	1,716
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	11,236
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	894
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	11,258
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	1,716
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	11,236



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	894
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	11,258
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	1,716
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	11,236
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	894
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	11,258
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	1,716
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	374
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	416
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	374
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	416
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	374
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	40

HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	416
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	374
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	416
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	10,151
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	436
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	7,610
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	324
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	5,073
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	212
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	2,536
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	101
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Female, Negative	86
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Female, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Male, Negative	61



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	1,727
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	109
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	403
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	1,308
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	122
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	687
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	129
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	704
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	104
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	735
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	139
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	704
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	104
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	755
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	129



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	704
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	104
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	735
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	129
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	704
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	104
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	735
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	129
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	966
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Positive	131
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	920
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	195
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	1



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	11,175
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	833
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	11,937
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	1,207
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	11,252
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	833
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	11,637
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	1,207
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	11,413
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	833
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	11,787
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	1,207
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	11,175
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	833



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	11,637
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	1,207
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Negative	1,516
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Positive	114
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Negative	1,516
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Positive	151
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Negative	1,516
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Positive	114
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	1,516
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Positive	200
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	1,516
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Positive	114
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	1,516
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	182
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	1,516
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Positive	114
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	1,516

HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	151
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	3,152
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	3,152
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	3,152
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	3,152
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	30
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	31
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	31
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	18
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	11
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2



TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	18
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	11
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	5
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	4,757
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	3,801
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	956
PMTCT_EID_DSD	Sum of Infant Age disaggregates	4,757
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	106,391
TX_CURR_DSD	Age/Sex: 15-19 Male	1,893
TX_CURR_DSD	Age/Sex: 15-19 Female	3,513
TX_CURR_DSD	Sum of age/sex disaggregates	5,406
TX_CURR_DSD	Age/Sex: <1	1,698
TX_CURR_DSD	Age/Sex: <1-9	2,398
TX_CURR_DSD	Age/Sex: 10-14 Male	1,422
TX_CURR_DSD	Age/Sex: 10-14 Female	1,173
TX_CURR_DSD	Age/Sex: 20-24 Male	2,464



TX_CURR_DSD	Age/Sex: 50+ Male	5,012
TX_CURR_DSD	Age/Sex: 20-24 Female	5,664
TX_CURR_DSD	Age/Sex: 50+ Female	6,046
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	7,470
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	4,776
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	11,632
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	5,991
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	8,623
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	6,434
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	13,649
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	16,453
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	21,247
TX_NEW_DSD	By Age/Sex: <1	16
TX_NEW_DSD	By Age/Sex: 1-9	1,010
TX_NEW_DSD	By Age/Sex: 10-14 Male	301
TX_NEW_DSD	By Age/Sex: 15-19 Male	407
TX_NEW_DSD	By Age/Sex: 20-24 Male	546
TX_NEW_DSD	By Age/Sex: 50+ Male	2,698
TX_NEW_DSD	By Age/Sex: 10-14 Female	73
TX_NEW_DSD	By Age/Sex: 15-19 Female	431
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,728
TX_NEW_DSD	By Age/Sex: 50+ Female	1,023
TX_NEW_DSD	Sum of Age/Sex disaggregates	7,207
TX_NEW_DSD	Pregnancy status	1,077

TX_NEW_DSD	Breastfeeding status	2,496
TX_NEW_DSD	FSW	96
TX_NEW_DSD	MSM	96
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,376
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	568
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	1,985
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	928
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	1,525
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,217
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	2,575
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	2,840
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	106,876
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	3,208
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	44,181
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	4,787
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	54,097
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	23,741
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting	26,019



	period, including those who have died, those who have stopped ART, and those lost to follow-up	
TX_RET_DSD	Numerator by Status: Pregnant	5,091
TX_RET_DSD	Numerator by Status: Breastfeeding	1,342
TX_RET_DSD	Denominator by Status: Pregnant	5,570
TX_RET_DSD	Denominator by Status: Breastfeeding	1,466
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	624
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,928
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	793
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13,396
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	659
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,873
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	834
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the	14,653



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
HTS_SELF_DSD	HTS_SELF_N_DSD	37,073
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	365
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Unassisted	733
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	365
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	733
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	1,099
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	1,099
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	733
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	733
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	1,469
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	1,469
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	1,469
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	1,469
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	1,469
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	1,469
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	1,469



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	1,469
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	1,469
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	1,469
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	1,469
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	1,469
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	1,469
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	1,469
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	1,469
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	1,469
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	1,469
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	1,469
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	1,469
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	1,469
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	365
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	351
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	365
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	376



HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	18,358
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	18,715
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	4,679
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	9,357
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	4,679
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	11,000
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	12,509
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	5,499
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	7,115
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	19,795
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	32,996
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	1,150
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	901
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	18,825
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	12,120
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	746
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	254
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	9,153



TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	9,642
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	32,996
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	19,795
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	106,131
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	4,243
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	3,183
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	57,312
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	41,393
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	106,131
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	106,131
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	106,131

Implementing Mechanism Details

Mechanism ID: 18322	Mechanism Name: Quality Improvement and Capacity for Impact Project (QICIP)
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University Mailman School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 559,947	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 100,000	
Total All Funding Sources and Applied Pipeline Amount: 659,947	
Funding Source	Funding Amount
GHP-State	559,947



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18322	
Mechanism Name:	Quality Improvement and Capacity for Impact Project (QICIP)	
Prime Partner Name:	Columbia University Mailman School of Public Health	
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	100,000
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	159,947
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	300,000

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18323	Mechanism Name: BroadReach
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Broadreach	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Approved



Total All Funding Sources: 9,727,234	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 9,727,234	
Funding Source	Funding Amount
GHP-State	9,727,234

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18323	
Mechanism Name:	BroadReach	
Prime Partner Name:	Broadreach	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	100,000
Strategic Area	Budget Code	Planned Amount
Care	HVTB	50,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	8,140,000
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,437,234

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 18324	Mechanism Name: University of Maryland ZCHECK
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland Baltimore	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,171,034	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,171,034	
Funding Source	Funding Amount
GHP-State	3,171,034

Cross-Cutting Budget Attribution(s)

Key Populations: FSW	300,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	90,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Monitoring and evaluation of MSM/TG programs
Human Resources for Health	920,000



Condom programming	100,000
Adolescent Girls and Young Women (AGYW)	440,000

Budget Code Information

Mechanism ID: 18324		
Mechanism Name: University of Maryland ZCHECK		
Prime Partner Name: University of Maryland Baltimore		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	300,000
Strategic Area	Budget Code	Planned Amount
Care	HVTB	100,000
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,284,550
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	986,484
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	400,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	100,000

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on	364

	oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	
PrEP_NEW_DSD	Female 20-24	61
PrEP_NEW_DSD	FSW	211
PrEP_NEW_DSD	MSM	5
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	61
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	109
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	91
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	18
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	18
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	3
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	3
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	390,217
PP_PREV_DSD	Age/sex: 10-14 Male	19,337
PP_PREV_DSD	Age/sex: 15-19 Male	19,604
PP_PREV_DSD	Age/sex: 20-24 Male	39,051
PP_PREV_DSD	Age/sex: 50+ Male	1,704
PP_PREV_DSD	Age/sex: 10-14 Female	19,601
PP_PREV_DSD	Age/sex: 15-19 Female	19,604
PP_PREV_DSD	Age/sex: 20-24 Female	94,089
PP_PREV_DSD	Age/sex: 50+ Female	1,706
PP_PREV_DSD	Sum of Age/Sex disaggregates	214,696
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	39,203
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	19,603
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	19,603
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	19,603
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	19,603
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	19,603
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	19,593
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	18,710



KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	3,695
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,336
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,359
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	19,735
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	82
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	18
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	143
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	36
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	117
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	14



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	166
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	62
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	99
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	100
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	164
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	73
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	125
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	991
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	139
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	37
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	127



HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	73
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	100
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	101
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	43
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	39
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	7
HTC_TST_DSD	By Key Population: FSW, Negative	2,153
HTC_TST_DSD	By Key Population: FSW, Positive	517
HTC_TST_DSD	By Key Population: MSM, Negative	77
HTC_TST_DSD	By Key Population: MSM, Positive	11
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	184
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	69
HTC_TST_DSD	By Key Population: TG, Negative	16
HTC_TST_DSD	By Key Population: TG, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14,	8



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	28
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	331
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	93
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	182
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	81
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	309
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	103
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	243
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	96
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	246
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	70
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	216
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	70
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	412
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9,	29



	Positive	
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	39
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	22
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	807
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	30
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	247
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	745
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	59
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	372
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	30
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	558
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	39
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	497
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	39
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 1-9, Negative	241
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 1-9, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29,	23



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	23
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	23
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	23
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	68
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	68
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	4



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	68
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	68
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	220
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	101
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	220
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	109
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	220
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	101
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	220



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	109
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	220
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	101
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	220
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	109
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	220
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	101
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	220
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	109
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	69
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	77
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	69
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	77
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	6



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	69
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	77
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	69
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	77
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Female, Negative	28
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Male, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	423
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	88
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24,	423



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	153
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	168
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	164
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	188
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	164
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	158
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	164
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	158
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	21



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	164
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	214
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	204
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Negative	372
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Negative	372
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Negative	372
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	372
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	372
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	372

	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	372
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	372
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	39
HTS_SELF_DSD	HTS_SELF_N_DSD	450
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Unassisted	9
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	9
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	13
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	13
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	9
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	9
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	17



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	17



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	14
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	222
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	228
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	57
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	114
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	57
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	134
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	155
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	66
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	88

Implementing Mechanism Details

Mechanism ID: 18325	Mechanism Name: UNZA ZEPACT+ Follow On
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Zambia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC



Total All Funding Sources: 250,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 250,000	
Funding Source	Funding Amount
GHP-State	250,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18325	
Mechanism Name:	UNZA ZEPACT+ Follow On	
Prime Partner Name:	University of Zambia	
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	150,000
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	100,000

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18327	Mechanism Name: CRS (FBO Follow-on 2)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 11,897,776	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 11,897,776	
Funding Source	Funding Amount
GHP-State	11,897,776

Cross-Cutting Budget Attribution(s)

Key Populations: FSW	50,000
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Key Populations: MSM and TG	30,000
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Condom programming	25,000
Human Resources for Health	1,613,860

Budget Code Information

Mechanism ID: 18327
Mechanism Name: CRS (FBO Follow-on 2)



Prime Partner Name: Catholic Relief Services		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	827,720
Strategic Area	Budget Code	Planned Amount
Care	HVTB	532,600
Strategic Area	Budget Code	Planned Amount
Care	PDCS	1,000,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	68,499
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	620,000
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,233,384
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	290,529
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	1,482,537
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	4,550,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	1,292,507

Implementing Mechanism Indicator Information



Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	6,032
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	44,654
PMTCT_ART_DSD	New on ART	2,919
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	3,113
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	44,654
PMTCT_STAT_DSD	Number of new ANC and L&D clients	47,165
PMTCT_STAT_DSD	By Age (Denominator): 10-14	68
PMTCT_STAT_DSD	By Age (Denominator): <15-19	9,491
PMTCT_STAT_DSD	By Age (Denominator): 20-24	13,819
PMTCT_STAT_DSD	By Age (Denominator): 50+	13
PMTCT_STAT_DSD	By Number of known positives: 15-19	8
PMTCT_STAT_DSD	By Number of known positives: 20-24	596
PMTCT_STAT_DSD	By Number of new positives: 15-19	59
PMTCT_STAT_DSD	By Number of new positives: 20-24	575
PMTCT_STAT_DSD	By Number of new negative: 15-19	1
PMTCT_STAT_DSD	By Number of new negative: 20-24	8,320
PMTCT_STAT_DSD	By Age (Numerator): 15-19	68
PMTCT_STAT_DSD	By Age (Numerator): 20-24	9,491
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	9,656
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	7,059
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	7,059
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	846
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	10,919



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	573
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	846
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	8,404
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	406
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	681
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	5,837
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	541
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	136
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	5,141
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	765
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	12,338
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	9,656
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	7,059
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	6,042
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	6,065
VMMC_CIRC_DSD	By Age: 0-60 days	7
VMMC_CIRC_DSD	By Age: 2 months - 9 years	18
VMMC_CIRC_DSD	By Age: 10-14	337
VMMC_CIRC_DSD	By Age: 15-19	2,232
VMMC_CIRC_DSD	By Age: 20-24	1,580
VMMC_CIRC_DSD	By Age: 25-29	763



VMMC_CIRC_DSD	By Age: 50+	158
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	4,307
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	5,070
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	6,065
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	338
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	339
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	293
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	460
PrEP_NEW_DSD	Female 20-24	76
PrEP_NEW_DSD	FSW	265
PrEP_NEW_DSD	MSM	57
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	76
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	137
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	114
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	23
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	23
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	6
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	5
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	7,195
PP_PREV_DSD	Age/sex: 10-14 Male	340
PP_PREV_DSD	Age/sex: 15-19 Male	360
PP_PREV_DSD	Age/sex: 20-24 Male	738
PP_PREV_DSD	Age/sex: 50+ Male	37
PP_PREV_DSD	Age/sex: 10-14 Female	360
PP_PREV_DSD	Age/sex: 15-19 Female	360
PP_PREV_DSD	Age/sex: 20-24 Female	1,720
PP_PREV_DSD	Age/sex: 50+ Female	40
PP_PREV_DSD	Sum of Age/Sex disaggregates	3,955



PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	720
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	360
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	360
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	360
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	360
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	360
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	360
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	360
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	1,109
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,109
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	268,794
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	600
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	331
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	592
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	152



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	518
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	317
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	405
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	379
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	49
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	3,727
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	70
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	204
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	47
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	233
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	58
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	8



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	194
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	247
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	152
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	25
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	147
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	26
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	459
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	5,002
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	41
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	2,713
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	7,527
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	132
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	1,912



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	77
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	6,947
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	212
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	3,643
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	245
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	4,502
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	400
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	4,192
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	643
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	22,836
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	553
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	132
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	36
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	120
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	4



HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	70
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	91
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	88
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	7,768
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	157
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	99
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	47
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	93
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	99
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	36
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	119
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	63



HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	247
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	183
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	236
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	1,415
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	1,415
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	471
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	297
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	163
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	855
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	87
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	369
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	69
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	887
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	112



HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	517
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	150
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	737
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	234
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	490
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	379
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	1,840
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	116
HTC_TST_DSD	By Key Population: FSW, Negative	537
HTC_TST_DSD	By Key Population: FSW, Positive	47
HTC_TST_DSD	By Key Population: MSM, Negative	79
HTC_TST_DSD	By Key Population: MSM, Positive	5
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	339
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	43
HTC_TST_DSD	By Key Population: TG, Negative	9
HTC_TST_DSD	By Key Population: TG, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	33
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	112
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	701



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	173
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	330
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	138
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	665
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	197
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	492
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	178
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	528
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	306
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	379
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	426
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	1,411
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	87
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	195
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	7,982
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	411
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	11,029
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	575
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	580
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	32



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	1,506
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	841
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	6,548
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	153
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	1,820
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	52
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	6,068
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	335
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	3,530
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	148
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	4,449
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	293
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	4,222
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	454
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	9,335
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	166



HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	47
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	24
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	400
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	122
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	367
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	184
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	274
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	245
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 1-9, Negative	283
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 1-9, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Female, Negative	49



HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 10-14, Male, Negative	23
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Negative	458
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Male, Negative	127
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	310
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative	407
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	244
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	233
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Negative	243
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Negative	233
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative	244
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Positive	2



HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Negative	233
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Negative	244
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative	233
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	244
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Negative	320
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Negative	312
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	492
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	168
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	479
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	229
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	494
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	168



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	469
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	229
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	492
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	168
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	469
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	229
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	492
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	168
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	479
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	229
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	284
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	299
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	284
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	299



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	284
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	299
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	284
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	299
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	114
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	114
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	25

HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	114
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	117
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	396
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	82
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	439
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	194
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	440
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	214
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	439
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	194
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	460

HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	212
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	459
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	189
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	521
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	212
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	459
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	189
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	450
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	212
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	3,459
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	280
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	3,467
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	517
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	3,459
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	280
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	3,467
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	517



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	3,459
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	280
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	3,467
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	517
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	3,459
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	280
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	3,467
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	517
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	65
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	69
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	65
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	69
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	65



HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	69
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	65
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	69
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	7,660
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	404
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	5,745
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	305
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	3,830
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	200
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	1,913
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	107
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Female, Negative	72
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Female, Positive	12



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Male, Negative	46
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	506
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	134
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 1-9, Unknown Sex, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	458
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	239
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	258
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	259
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	238
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	30



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	246
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	248
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	246
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	238
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	246
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	321
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	301
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	87
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	93



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	52
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	87
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	93
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	52
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	87
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	93
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	52
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	87
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	93
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	52
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	3,296
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	246
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	3,427
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	352



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	3,296
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	246
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	3,427
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	352
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	3,358
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	246
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	3,448
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	352
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	3,296
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	246
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	3,548
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	352
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Negative	184
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Negative	184
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Negative	184

HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	184
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	184
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	184
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	184
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	184
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	295
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	295
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	295
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	3



HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	295
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	3
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,719
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	3,719
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	84
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,275
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	78
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,282
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	84
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,275
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	78
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,282
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,028



TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	70
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	753
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	90
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,099
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	6,032
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	4,829
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,203
PMTCT_EID_DSD	Sum of Infant Age disaggregates	6,032
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	126,460
TX_CURR_DSD	Age/Sex: 15-19 Male	2,289
TX_CURR_DSD	Age/Sex: 15-19 Female	2,930
TX_CURR_DSD	Sum of age/sex disaggregates	5,219
TX_CURR_DSD	Age/Sex: <1	1,578
TX_CURR_DSD	Age/Sex: <1-9	3,490
TX_CURR_DSD	Age/Sex: 10-14 Male	1,312
TX_CURR_DSD	Age/Sex: 10-14 Female	1,928
TX_CURR_DSD	Age/Sex: 20-24 Male	2,359
TX_CURR_DSD	Age/Sex: 50+ Male	7,797



TX_CURR_DSD	Age/Sex: 20-24 Female	6,507
TX_CURR_DSD	Age/Sex: 50+ Female	9,334
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	9,209
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	4,376
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	11,296
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	6,321
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	11,367
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	8,492
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	17,510
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	18,356
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	19,451
TX_NEW_DSD	By Age/Sex: <1	34
TX_NEW_DSD	By Age/Sex: 1-9	1,176
TX_NEW_DSD	By Age/Sex: 10-14 Male	175
TX_NEW_DSD	By Age/Sex: 15-19 Male	515
TX_NEW_DSD	By Age/Sex: 20-24 Male	469
TX_NEW_DSD	By Age/Sex: 50+ Male	3,151
TX_NEW_DSD	By Age/Sex: 10-14 Female	136
TX_NEW_DSD	By Age/Sex: 15-19 Female	620
TX_NEW_DSD	By Age/Sex: 20-24 Female	550
TX_NEW_DSD	By Age/Sex: 50+ Female	1,997
TX_NEW_DSD	Sum of Age/Sex disaggregates	7,613
TX_NEW_DSD	Pregnancy status	2,871
TX_NEW_DSD	Breastfeeding status	4,020



TX_NEW_DSD	FSW	953
TX_NEW_DSD	MSM	1,028
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,240
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	677
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	1,371
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	948
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	1,294
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,064
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	1,751
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	2,273
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	126,242
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	3,849
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	50,185
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	4,315
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	67,984
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	29,387
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	32,003



	stopped ART, and those lost to follow-up	
TX_RET_DSD	Numerator by Status: Pregnant	5,294
TX_RET_DSD	Numerator by Status: Breastfeeding	1,395
TX_RET_DSD	Denominator by Status: Pregnant	5,804
TX_RET_DSD	Denominator by Status: Breastfeeding	1,528
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,127
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	12,837
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,481
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13,942
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,236
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	13,858
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,630
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	15,279



	including those who have died, those who have stopped ART, and those lost to follow-up)	
HTS_SELF_DSD	HTS_SELF_N_DSD	34,097
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	339
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Unassisted	672
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	339
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	672
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	1,011
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	1,011
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	672
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	672
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	1,347
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	1,347
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	1,347
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	1,347
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	1,347
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	1,347
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	1,347
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	1,347



	Male, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	1,347
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	1,347
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	1,347
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	1,347
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	1,347
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	1,346
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	1,347
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	1,346
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	1,347
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	1,346
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	1,347
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	1,345
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	338
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	336
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	338
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	381
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	16,888



HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	17,209
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	4,301
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	8,607
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	4,301
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	10,115
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	11,695
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	5,058
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Unassisted	6,213
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	16,754
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	27,760
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	829
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	782
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	15,679
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	10,470
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	636
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	266
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	7,742
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	8,110



TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	27,760
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	16,754
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	135,088
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	5,401
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	4,052
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	72,947
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	52,688
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	135,088
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	135,088
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	135,088

Implementing Mechanism Details

Mechanism ID: 18332	Mechanism Name: ICAP KP
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University Mailman School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 200,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 200,000	
Funding Source	Funding Amount
GHP-State	200,000



Cross-Cutting Budget Attribution(s)

Key Populations: FSW	50,000
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Collection and use of strategic information on SWs and clients
Key Populations: MSM and TG	20,000
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Collection and use of strategic information
Condom programming	30,000

Budget Code Information

Mechanism ID:	18332	
Mechanism Name:	ICAP KP	
Prime Partner Name:	Columbia University Mailman School of Public Health	
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	200,000

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18346	Mechanism Name: U.S. Peace Corps
Funding Agency: PC	Procurement Type: USG Core
Prime Partner Name: U.S. Peace Corps	

Approved



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 376,896	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 376,896	
Funding Source	Funding Amount
GHP-State	376,896

Cross-Cutting Budget Attribution(s)

Adolescent Girls and Young Women (AGYW)	67,621
---	--------

Budget Code Information

Mechanism ID: 18346		
Mechanism Name: U.S. Peace Corps		
Prime Partner Name: U.S. Peace Corps		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	18,805
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	179,045
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	179,046
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	70,991
PP_PREV_DSD	Age/sex: 10-14 Male	3,403
PP_PREV_DSD	Age/sex: 15-19 Male	3,549
PP_PREV_DSD	Age/sex: 20-24 Male	7,265
PP_PREV_DSD	Age/sex: 50+ Male	359
PP_PREV_DSD	Age/sex: 10-14 Female	3,549
PP_PREV_DSD	Age/sex: 15-19 Female	3,550
PP_PREV_DSD	Age/sex: 20-24 Female	17,013
PP_PREV_DSD	Age/sex: 50+ Female	400
PP_PREV_DSD	Sum of Age/Sex disaggregates	39,088
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	7,096
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	3,549
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	3,549
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	3,549
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	3,549
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	3,549
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	3,543
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	3,519



Implementing Mechanism Details

Mechanism ID: 18487	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18527	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18528	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18530	Mechanism Name: JHPIEGO HRH
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,000,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 200,000	
Total All Funding Sources and Applied Pipeline Amount: 1,200,000	
Funding Source	Funding Amount
GHP-State	1,000,000

Cross-Cutting Budget Attribution(s)

Approved



(No data provided.)

Budget Code Information

Mechanism ID: 18530		
Mechanism Name: JHPIEGO HRH		
Prime Partner Name: JHPIEGO		
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	700,000
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	300,000

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18532	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18652	Mechanism Name: Breakthrough ACTION
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Johns Hopkins University Center for Communication Programs	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 656,517	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 656,517	
Funding Source	Funding Amount
GHP-State	656,517

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18652	
Mechanism Name:	Breakthrough ACTION	
Prime Partner Name:	Johns Hopkins University Center for Communication Programs	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	656,517
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18669	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70432	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70453	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70455	Mechanism Name: GHSC-TA Central Task Order
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Chemonics International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
-------------------------------------	--------------------------------------



Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70455		
Mechanism Name: GHSC-TA Central Task Order		
Prime Partner Name: Chemonics International		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	290,208
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	OHSS	2,800,322
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Approved



Implementing Mechanism Indicator Information

(No data provided.)



Agency Information - Costs of Doing Business
U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		586,000		586,000	0	586,000
ICASS		1,589,538		1,589,538	0	1,589,538
Management Meetings/Professional Development		714,000		714,000	0	714,000
Non-ICASS Administrative Costs		524,400		524,400	0	524,400
Staff Program Travel		660,000	0	660,000	0	660,000
USG Staff Salaries and Benefits - Internationally Recruited		2,020,457	0	2,020,457	0	2,020,457
USG Staff Salaries and Benefits - Locally Recruited		3,820,390	0	3,820,390	0	3,820,390
Total	0	9,914,785	0	9,914,785	0	9,914,785



U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
ICASS		0		0	120,000	120,000
Management Meetings/Professional Development		0		0	100,000	100,000
Non-ICASS Administrative Costs		0		0	50,000	50,000
Non-ICASS Motor Vehicles		0		0	6,000	6,000
Staff Program Travel		0		0	74,000	74,000
USG Staff Salaries and Benefits - Internationally Recruited		0		0	370,000	370,000
USG Staff Salaries and Benefits - Locally Recruited		0		0	260,000	260,000
Total	0	0	0	0	980,000	980,000

U.S. Department of Health and Human Services/Centers for Disease Control and



Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing		264,510		264,510	0	264,510
Computers/IT Services		791,698		791,698	0	791,698
ICASS		2,799,136		2,799,136	0	2,799,136
Institutional Contractors		400,000		400,000	0	400,000
Management Meetings/Professional Development		18,480		18,480	0	18,480
Non-ICASS Administrative Costs		759,960		759,960	0	759,960
Staff Program Travel		1,105,000		1,105,000	0	1,105,000
USG Staff Salaries and Benefits - Internationally Recruited	2,412,531	1,452,498		3,865,029	0	3,865,029
USG Staff Salaries and Benefits - Locally Recruited	0	3,052,945		3,052,945	0	3,052,945
Total	2,412,531	10,644,227	0	13,056,758	0	13,056,758



U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		18,433		18,433	0	18,433
ICASS		531,520		531,520	0	531,520
Management Meetings/Professional Development		102,810		102,810	0	102,810
Non-ICASS Administrative Costs		284,080		284,080	0	284,080
Staff Program Travel		95,110		95,110	0	95,110
USG Staff Salaries and Benefits - Internationally Recruited		228,024		228,024	223,817	451,841
USG Staff Salaries and Benefits - Locally Recruited		429,098		429,098	0	429,098
Total	0	1,689,075	0	1,689,075	223,817	1,912,892

U.S. Peace Corps



Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Non-ICASS Administrative Costs		529,687		529,687	0	529,687
Non-ICASS Motor Vehicles		132,471		132,471	0	132,471
Peace Corps Volunteer Costs		2,934,602		2,934,602	0	2,934,602
Staff Program Travel		149,718		149,718	0	149,718
USG Staff Salaries and Benefits - Locally Recruited		947,247		947,247	0	947,247
Total	0	4,693,725	0	4,693,725	0	4,693,725